Document:

Exhibit 10.1

 

LOAN
AND SECURITY AGREEMENT

 

THIS LOAN AND SECURITY
AGREEMENT (this “Agreement”) dated as of January 5, 2018 (the “Effective Date”) among
SILICON VALLEY BANK, a California corporation (“Bank”), and LIPOCINE INC., a Delaware corporation
(“Parent”), and LIPOCINE OPERATING INC., a Delaware corporation (“Lipocine Operating”
and together with Parent, individually and collectively, jointly and severally, “Borrower”), provides the terms
on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:

 

		1	ACCOUNTING AND OTHER TERMS

 

Accounting terms not
defined in this Agreement shall be construed following GAAP. Calculations and determinations must be made following GAAP; provided
that if at any time any change in GAAP would affect the computation of any financial covenant or requirement set forth in any Loan
Document, and either Borrower or Bank shall so request, Borrower and Bank shall negotiate in good faith to amend such financial
covenant or requirement to preserve the original intent thereof in light of such change in GAAP; provided, further, that until
so amended, (a) such financial covenant or requirement shall continue to be computed in accordance with GAAP prior to such change
therein and (b) Borrower shall provide Bank financial statements and other documents required under this Agreement or as reasonably
requested hereunder setting forth a reconciliation between calculations of such financial covenant or requirement made before and
after giving effect to such change in GAAP. Capitalized terms not otherwise defined in this Agreement shall have the meanings set
forth in Section 13. All other terms contained in this Agreement, unless otherwise indicated, shall have the meanings provided
by the Code to the extent such terms are defined therein.

 

		2	LOAN AND TERMS OF PAYMENT

 

2.1         Promise
to Pay. Borrower hereby unconditionally promises to pay Bank the outstanding principal amount of all Credit Extensions and
accrued and unpaid interest thereon as and when due in accordance with this Agreement.

 

2.1.1      Growth
Capital Loan.

 

(a)          Availability.
Subject to the terms and conditions of this Agreement, Bank agrees to make a single advance to Borrower (the “Growth Capital
Advance”) on or about the Effective Date in an amount equal to the Growth Capital Loan Commitment.

 

     

     

    

 

(b)          Repayment
of Growth Capital Advance.

 

(i)          Interest-Only
Payments. For the Growth Capital Advance, Borrower shall make monthly payments of interest-only commencing on the first (1st)
Business Day of the first (1st) month following the month in which the Funding Date occurs with respect to the Growth
Capital Advance and continuing thereafter during the Interest-Only Period, on the first (1st) Business Day of each successive
month.

 

(ii)         Principal
and Interest Payments. Following the last day of the Interest-Only Period, Borrower shall make consecutive equal monthly payments
of principal, plus monthly payments of accrued and unpaid interest, commencing on the first (1st) Business Day of the first (1st)
month after the Interest-Only Period (the “Conversion Date”), in amounts that would fully amortize the Growth
Capital Advance, as of the Conversion Date, over the Repayment Period. The Final Payment and all unpaid principal and accrued and
unpaid interest on the Growth Capital Advance is due and payable in full on the Growth Capital Maturity Date.

 

(c)          Voluntary
Prepayment. Borrower shall have the option to prepay the Growth Capital Advance in full, provided Borrower (i) shall provide
written notice to Bank of its election to prepay the Growth Capital Advance at least ten (10) days prior to such prepayment and
(ii) pays, on the date of such prepayment, (A) all outstanding principal and accrued but unpaid interest, plus (B) the Prepayment
Fee, plus (C) the Final Payment, plus (D) all other sums, including Bank Expenses, if any, that shall have become due and payable.

 

(d)          Mandatory
Prepayment Upon an Acceleration. If the Growth Capital Advance is accelerated following the occurrence of an Event of Default,
Borrower shall immediately pay to Bank an amount equal to the sum of (i) all outstanding principal and accrued but unpaid
interest, plus (ii) the Prepayment Fee, plus (iii) the Final Payment, plus (iv) all other sums, including Bank Expenses, if any,
that shall have become due and payable.

 

		2.2	Payment of Interest on the Credit Extensions.

 

(a)          Interest
Rate. Subject to Section 2.2(b), the principal amount outstanding for the Growth Capital Advance shall accrue interest at a
floating per annum rate equal to one percentage point (1.0%) above the Prime Rate, which shall be payable monthly in accordance
with Section 2.2(d) below.

 

(b)          Default
Rate. Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall bear interest at
a rate per annum which is five percentage points (5.00%) above the rate that is otherwise applicable thereto (the “Default
Rate”). Fees and expenses which are required to be paid by Borrower pursuant to the Loan Documents (including, without
limitation, Bank Expenses) but are not paid when due shall bear interest until paid at a rate equal to the highest rate applicable
to the Obligations. Payment or acceptance of the increased interest rate provided in this Section 2.2(b) is not a permitted
alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights
or remedies of Bank.

 

    	 	2	 

     

    

  

(c)          Adjustment
to Interest Rate. Changes to the interest rate of any Credit Extension based on changes to the Prime Rate shall be effective
on the effective date of any change to the Prime Rate and to the extent of any such change.

 

(d)          Payment;
Interest Computation. Interest is payable monthly on the first calendar day of each month and shall be computed on the basis
of a 360-day year for the actual number of days elapsed. In computing interest, (i) all payments received after 12:00 p.m. Pacific
time on any day shall be deemed received at the opening of business on the next Business Day, and (ii) the date of the making of
any Credit Extension shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension
is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension.

 

		2.3	Fees. Borrower shall pay to Bank the following:

 

(a)          Final
Payment. The Final Payment, when due hereunder;

 

(b)          Prepayment
Fee. The Prepayment Fee, when due hereunder; and

 

(c)          Expenses.
All Bank Expenses (including reasonable attorneys’ fees and expenses, plus expenses for documentation and negotiation of
this Agreement) incurred through and after the Effective Date, when due (or, if no stated due date, upon demand by Bank). Bank
shall apply to such Bank Expenses the $25,000 good faith deposit that the Borrower deposited with the Bank prior to the Effective
Date and, following such application, shall refund to the Borrower any remaining portion of such deposit.

 

(d)          Fees
Fully Earned. Unless otherwise provided in this Agreement or in a separate writing by Bank, Borrower shall not be entitled
to any credit, rebate, or repayment of any fees earned by Bank pursuant to this Agreement notwithstanding any termination of this
Agreement or the suspension or termination of Bank’s obligation to make loans and advances hereunder. Bank may deduct amounts
owing by Borrower under the clauses of this Section 2.3 pursuant to the terms of Section 2.4(c). Bank shall provide Borrower written
notice of deductions made from the Designated Deposit Account pursuant to the terms of the clauses of this Section 2.3.

 

		2.4	Payments; Application of Payments; Debit of Accounts.

 

(a)          All
payments to be made by Borrower under any Loan Document shall be made in immediately available funds in Dollars, without setoff
or counterclaim, before 12:00 p.m. Pacific time on the date when due. Payments of principal and/or interest received after 12:00
p.m. Pacific time are considered received at the opening of business on the next Business Day. When a payment is due on a day that
is not a Business Day, the payment shall be due the next Business Day, and additional fees or interest, as applicable, shall continue
to accrue until paid.

 

(b)          Prior
to the occurrence of an Event of Default, payments shall be applied first to any Obligations that are then due and owing and then
thereafter as determine by Bank. Upon and during the continuance of an Event of Default, Bank has the exclusive right to determine
the order and manner in which all payments with respect to the Obligations may be applied. Except as specified immediately above,
Borrower shall have no right to specify the order or the accounts to which Bank shall allocate or apply any payments required to
be made by Borrower to Bank or otherwise received by Bank under this Agreement when any such allocation or application is not specified
elsewhere in this Agreement.

 

    	 	3	 

     

    

 

(c)          Bank
may debit any of Borrower’s deposit accounts, including the Designated Deposit Account, for principal and interest payments
or any other amounts Borrower owes Bank when due. These debits shall not constitute a set-off.

 

2.5         Withholding.
Payments received by Bank from Borrower under this Agreement will be made free and clear of and without deduction for any and all
present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any Governmental
Authority (including any interest, additions to tax or penalties applicable thereto, but excluding, for the avoidance of doubt,
taxes based on the net income of Bank). Specifically, however, if at any time any Governmental Authority, applicable law, regulation
or international agreement requires Borrower to make any withholding or deduction from any such payment or other sum payable hereunder
to Bank, Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable
hereunder will be increased to the extent necessary to ensure that, after the making of such required withholding or deduction,
Bank receives a net sum equal to the sum which it would have received had no withholding or deduction been required, and Borrower
shall pay the full amount withheld or deducted to the relevant Governmental Authority. Borrower will, upon request, furnish Bank
with proof reasonably satisfactory to Bank indicating that Borrower has made such withholding payment; provided, however, that
Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith
by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower. The agreements
and obligations of Borrower contained in this Section 2.5 shall survive the termination of this Agreement.

 

		3	CONDITIONS OF LOANS

 

3.1         Conditions
Precedent to Initial Credit Extension. Bank’s obligation to make the initial Credit Extension is subject to the condition
precedent that Bank shall have received, in form and substance satisfactory to Bank, such documents, and completion of such other
matters, as Bank may reasonably deem necessary or appropriate, including, without limitation:

 

(a)          duly
executed signatures in PDF to the Loan Documents, followed by duly executed original signatures to the Loan Documents within five
(5) Business Days;

 

(b)          the
Operating Documents and long-form good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State
(or equivalent agency) of Borrower’s and such Subsidiaries’ jurisdiction of organization or formation and each jurisdiction
in which Borrower and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior
to the Effective Date;

 

(c)          duly
executed original signatures to the completed Borrowing Resolutions for Borrower;

 

    	 	4	 

     

    

 

(d)          certified
copies, dated as of a recent date, of financing statement searches, as Bank may request, accompanied by written evidence (including
any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens, or
have been, or in connection with the initial Credit Extension will be, terminated or released;

 

(e)          the
Perfection Certificate executed by Borrower; and

 

(f)          payment
of the fees and Bank Expenses then due as specified in Section 2.3 hereof.

 

3.2         Conditions
Precedent to all Credit Extensions. Bank’s obligations to make each Credit Extension, including the initial Credit Extension,
are subject to the following conditions precedent:

 

(a)          timely
receipt of an executed Payment/Advance Form;

 

(b)          the
representations and warranties in this Agreement shall be true, accurate, and complete in all material respects on the date of
the Payment/Advance Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall
not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof;
and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate
and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result
from the Credit Extension. Each Credit Extension is Borrower’s representation and warranty on that date that the representations
and warranties in this Agreement remain true, accurate, and complete in all material respects; provided, however, that such materiality
qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in
the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall
be true, accurate and complete in all material respects as of such date; and

 

(c)          Bank
determines to its satisfaction that no Material Adverse Change has occurred.

 

3.3         Covenant
to Deliver.

 

(a)          Except
as otherwise provided in Section 3.3(b), Borrower agrees to deliver to Bank each item required to be delivered to Bank under this
Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that a Credit Extension made prior to the
receipt by Bank of any such item shall not constitute a waiver by Bank of Borrower’s obligation to deliver such item, and
any such Credit Extension in the absence of a required item shall be made in Bank’s sole discretion.

 

    	 	5	 

     

    

 

(b)          Unless
otherwise provided in writing, within thirty (30) days after the Effective Date:

 

(i)          Borrower
shall have used commercially reasonable efforts to obtain and deliver to Bank a landlord’s consent in favor of Bank for Borrower’s
location in the State of Utah by the landlord thereof, in form and substance reasonably satisfactory to Bank, together with the
duly executed original signatures thereto (for the avoidance of doubt, such commercially reasonable efforts standard shall apply
so long as the aggregate value of Collateral held in such location does not exceed $100,000);

 

(ii)         Borrower
shall have delivered to Bank evidence reasonably satisfactory to Bank that the insurance policies and endorsements required by
Section 6.5 hereof are in full force and effect, together with appropriate evidence showing lender loss payable and/or additional
insured clauses and cancellation notice to Bank (or endorsements reflecting the same) in favor of Bank;

 

(iii)        Borrower
shall have used commercially reasonable efforts to obtain and deliver to Bank a Control Agreement or other appropriate instrument
with respect to each of the Chase Accounts (other than deposit accounts exclusively used for payroll, payroll taxes and other employee
wage and benefit payments to or for the benefit of Borrower’s employees and identified to Bank by Borrower as such), in form
and substance reasonably satisfactory to Bank; provided that if, within such thirty (30) day period, Borrower shall have been unable
to obtain and deliver such a Control Agreement to Bank, then Borrower shall close such Chase Accounts and transfer the deposits
held therein to accounts held with Bank and/or Bank’s Affiliates on or before that date which is one hundred twenty (120)
days following the Effective Date; and

 

(iv)        Borrower
shall have delivered to Bank the original stock certificates representing all the shares of Lipocine Operating, and the stock certificates
representing the shares of any other Subsidiaries of Borrower which constitute Collateral, in each case, to the extent such shares
are certificated, together with stock powers signed in blank by the applicable owner of such shares for each certificate so delivered,
all in form and substance reasonably satisfactory to Bank.

 

3.4         Procedures
for Borrowing. Subject to the prior satisfaction of all other applicable conditions to the making of a Credit Extension set
forth in this Agreement, to obtain a Credit Extension, Borrower shall notify Bank (which notice shall be irrevocable) by electronic
mail, facsimile, or telephone by 12:00 p.m. Pacific time on the Funding Date of the Credit Extension. Together with any such electronic
or facsimile notification, Borrower shall deliver to Bank by electronic mail or facsimile a completed Payment/Advance Form executed
by a Responsible Officer or his or her designee. Bank may rely on any telephone notice given by a person who Bank believes is a
Responsible Officer or designee. Bank shall credit Credit Extensions to the Designated Deposit Account. Bank may make Credit Extensions
under this Agreement based on instructions from a Responsible Officer or his or her designee or without instructions if the Credit
Extensions are necessary to meet Obligations that have become due.

 

    	 	6	 

     

    

 

		4	CREATION OF SECURITY INTEREST

 

4.1         Grant
of Security Interest. Borrower hereby grants Bank, to secure the payment and performance in full of all of the Obligations,
a continuing security interest in, and pledges to Bank, the Collateral, wherever located, whether now owned or hereafter acquired
or arising, and all proceeds and products thereof.

 

Borrower acknowledges
that it previously has entered, and/or may in the future enter, into Bank Services Agreements with Bank.  Regardless of the
terms of any Bank Services Agreement, Borrower agrees that any amounts Borrower owes Bank thereunder shall be deemed to be Obligations
hereunder and that it is the intent of Borrower and Bank to have all such Obligations secured by the first priority perfected security
interest in the Collateral granted herein (subject only to Permitted Liens that may have superior priority to Bank’s Lien
in this Agreement).

 

If this Agreement is
terminated, Bank’s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations)
are paid in full in cash, and at such time, Bank shall, at Borrower’s sole cost and expense, terminate its security interest
in the Collateral and all rights therein shall revert to Borrower. In the event (x) all Obligations (other than inchoate indemnity
obligations), except for Bank Services, are paid in full in cash, and (y) this Agreement is terminated, Bank shall terminate the
security interest granted herein upon Borrower providing cash collateral acceptable to Bank in its good faith business judgment
for Bank Services, if any. In the event such Bank Services consist of outstanding Letters of Credit, Borrower shall provide to
Bank cash collateral in an amount equal to (x) if such Letters of Credit are denominated in Dollars, then at least one hundred
five percent (105.0%); and (y) if such Letters of Credit are denominated in a Foreign Currency, then at least one hundred
ten percent (110.0%), of the Dollar Equivalent of the face amount of all such Letters of Credit plus all interest, fees, and costs
due or to become due in connection therewith (as estimated by Bank in its good faith business judgment), to secure all of the Obligations
relating to such Letters of Credit.

 

    	 	7	 

     

    

 

4.2         Priority
of Security Interest. Borrower represents, warrants, and covenants that the security interest granted herein is and shall at
all times continue to be a first priority perfected (to the extent perfection may be achieved by the filing of financing statements
or by control, or in the case of investment property, by possession) security interest in the Collateral (subject only to Permitted
Liens that are permitted pursuant to the terms of this Agreement to have superior priority to Bank’s Lien under this Agreement).
If Borrower shall acquire a commercial tort claim with a value exceeding Twenty-Five Thousand Dollars ($25,000) (which limitation
shall not apply if an Event of Default is continuing), Borrower shall promptly notify Bank in a writing signed by Borrower of the
general details thereof and grant to Bank in such writing a security interest therein and in the proceeds thereof, all upon the
terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Bank.

 

4.3         Authorization
to File Financing Statements. Borrower hereby authorizes Bank to file financing statements, without notice to Borrower, with
all appropriate jurisdictions to perfect or protect Bank’s interest or rights hereunder. Such financing statements may indicate
the Collateral as “all assets of the Debtor” or words of similar effect, or as being of an equal or lesser scope, or
with greater detail, all in Bank’s discretion.

 

		5	REPRESENTATIONS AND WARRANTIES

 

Borrower represents
and warrants as follows:

 

5.1         Due
Organization, Authorization; Power and Authority. Borrower is duly existing and in good standing as a Registered Organization
in its jurisdiction of formation and is qualified and licensed to do business and is in good standing in any jurisdiction in which
the conduct of its business or its ownership of property requires that it be qualified except where the failure to do so could
not reasonably be expected to have a material adverse effect on Borrower’s business. In connection with this Agreement, Borrower
has delivered to Bank completed certificates each signed by Borrower, entitled “Perfection Certificate” (each, a “Perfection
Certificate”). Borrower represents and warrants to Bank that (a) Borrower’s exact legal name is that indicated
on the Perfection Certificate and on the signature page hereof; (b) Borrower is an organization of the type, and is organized
in the jurisdiction, set forth in the Perfection Certificate; (c) the Perfection Certificate accurately sets forth Borrower’s
organizational identification number or accurately states that Borrower has none; (d) the Perfection Certificate (as updated from
time to time pursuant to the terms hereof) accurately sets forth , as of the date thereof, Borrower’s place of business,
or, if more than one, its chief executive office as well as Borrower’s mailing addresses (if different than their chief executive
office); (e) except as set forth in the Perfection Certificate, Borrower (and each of their predecessors) has not, in the
past five (5) years, changed its jurisdiction of formation, organizational structure or type, or any organizational number assigned
by its jurisdiction; and (f) all other information set forth on the Perfection Certificate (as updated from time to time pursuant
to the terms hereof) pertaining to Borrower and each of its Subsidiaries is accurate and complete (it being understood and agreed
that Borrower may from time to time update certain information in the Perfection Certificate after the Effective Date by delivering
a new Perfection Certificate or by disclosing such updates on a quarterly Compliance Certificate to the extent such updates result
from actions, transactions or circumstances that are not prohibited by this Agreement and all references to “Perfection Certificate”
shall hereinafter be deemed to be a reference to the updated Perfection Certificate)). If Borrower is not now a Registered Organization
but later becomes one, Borrower shall promptly notify Bank of such occurrence and provide Bank with Borrower’s organizational
identification number.

 

    	 	8	 

     

    

 

The execution, delivery
and performance by Borrower of the Loan Documents to which it is a party have been duly authorized, and do not (i) conflict with
any of Borrower’s organizational documents, (ii) contravene, conflict with, constitute a default under or violate any
material Requirement of Law, (iii) contravene, conflict with or violate any applicable order, writ, judgment, injunction,
decree, determination or award of any Governmental Authority by which Borrower or any of its Subsidiaries or any of their property
or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental
Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full
force and effect and filings to perfect the security interests created by the Loan Documents) or (v) conflict with, contravene,
constitute a default or breach under, or result in or permit the termination or acceleration of, any material agreement by which
Borrower is bound. Borrower is not in default under any agreement to which it is a party or by which it is bound in which the default
could reasonably be expected to have a material adverse effect on Borrower’s business.

 

5.2         Collateral.
Borrower has good title to, rights in, and the power to transfer each item of the Collateral upon which it purports to grant a
Lien hereunder, free and clear of any and all Liens except Permitted Liens. Borrower has no Collateral Accounts at or with any
bank or financial institution other than Bank or Bank’s Affiliates except for the Collateral Accounts described in the Perfection
Certificate delivered to Bank in connection herewith and which Borrower has taken such actions as are necessary to give Bank a
perfected security interest therein, pursuant to the terms of Section 6.6(b). The Accounts are bona fide, existing obligations
of the Account Debtors.

 

The Collateral is not
in the possession of any third party bailee (such as a warehouse) except as otherwise provided in the Perfection Certificate (as
updated from time to time pursuant to the terms of Section 5.1) and except as permitted by Section 7.2. None of the components
of the Collateral shall be maintained at locations other than as provided in the Perfection Certificate(as updated from time to
time pursuant to the terms of Section 5.1) or as permitted pursuant to Section 7.2.

 

All Inventory is in
all material respects of good and marketable quality, free from material defects.

 

Borrower is the sole
owner of the Intellectual Property which it owns or purports to own except for (a) non-exclusive licenses granted to its customers
in the ordinary course of business, (b) over-the-counter software that is commercially available to the public, (c) material Intellectual
Property licensed to Borrower and noted on the Perfection Certificate (as updated from time to time pursuant to Section 5.1), and
(d) non-material Intellectual Property which has been abandoned or terminated in the exercise of Borrower’s reasonable business
judgment in accordance with the terms of this Agreement. Each Patent which it owns or purports to own and which is material to
Borrower’s business is valid and enforceable, and no part of the Intellectual Property which Borrower owns or purports to
own and which is material to Borrower’s business has been judged by the United States Patent and Trademark Office, the United
States Copyright Office, or any court of competent jurisdiction invalid or unenforceable, in whole or in part. To the best of Borrower’s
knowledge, no claim has been made that any part of the Intellectual Property violates the rights of any third party except to the
extent such claim would not reasonably be expected to have a material adverse effect on Borrower’s business.

 

    	 	9	 

     

    

 

Except as noted on
the Perfection Certificate (as updated from time pursuant to Section 5.1) or as disclosed to Bank pursuant to Section 6.8(b) from
time to time, Borrower is not a party to, nor is it bound by, any Restricted License.

 

5.3           Litigation.
Except as noted on the Perfection Certificate (as updated from time to time pursuant to Section 5.1), there are no actions or proceedings
pending or, to the knowledge of any Responsible Officer, threatened in writing by or against Borrower or any of its Subsidiaries
involving more than One Hundred Thousand Dollars ($100,000) individually or in the aggregate.

 

5.4           No
Material Deviation in Financial Statements. All consolidated financial statements for Borrower and any of its Subsidiaries
delivered to Bank fairly present in all material respects Borrower’s consolidated financial condition and Borrower’s
consolidated results of operations, in each case as of the respective dates thereof, all in accordance with GAAP, subject, in the
case of interim financial statements, to the absence of footnotes and normal year-end adjustments. There has not been any material
deterioration in Borrower’s consolidated financial condition since the date of the most recent financial statements submitted
to Bank.

 

5.5           Solvency.
The fair salable value of Borrower’s consolidated assets (including goodwill minus disposition costs) exceeds the fair value
of Borrower’s liabilities; Borrower is not left with unreasonably small capital after the transactions in this Agreement;
and Borrower is able to pay its debts (including trade debts) as they mature.

 

5.6           Regulatory
Compliance. Borrower is not an “investment company” or a company “controlled” by an “investment
company” under the Investment Company Act of 1940, as amended. Borrower is not engaged as one of its important activities
in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower (a) has
complied in all material respects with all Requirements of Law, and (b) has not violated any Requirements of Law the violation
of which could reasonably be expected to have a material adverse effect on its business. None of Borrower’s or any of its
Subsidiaries’ properties or assets has been used by Borrower or any Subsidiary or, to the best of Borrower’s knowledge,
by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than legally. Borrower
and each of its Subsidiaries have obtained all consents, approvals and authorizations of, made all declarations or filings with,
and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently
conducted in all material respects.

 

5.7           Subsidiaries;
Investments. Borrower does not own any stock, partnership, or other ownership interest or other equity securities except for
Permitted Investments.

 

    	 	10	 

     

    

  

5.8           Tax
Returns and Payments; Pension Contributions. Borrower has timely filed all required tax returns and reports, and Borrower has
timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except (a) to
the extent such taxes are being contested in good faith by appropriate proceedings promptly instituted and diligently conducted,
so long as such reserve or other appropriate provision, if any, as shall be required in conformity with GAAP shall have been made
therefor, or (b) if such taxes, assessments, deposits and contributions do not, individually or in the aggregate, exceed Ten Thousand
Dollars ($10,000).

 

To the extent Borrower
defers payment of any contested taxes, Borrower shall (i) notify Bank in writing of the commencement of, and any material development
in, the proceedings, and (ii) post bonds or take any other steps required to prevent the Governmental Authority levying such contested
taxes from obtaining a Lien upon any of the Collateral that is other than a “Permitted Lien.” Borrower is unaware of
any claims or adjustments proposed for any of Borrower's prior tax years which could result in additional taxes becoming due and
payable by Borrower in excess of Ten Thousand Dollars ($10,000). Borrower has paid all amounts necessary to fund all present pension,
profit sharing and deferred compensation plans in accordance with their terms, and Borrower has not withdrawn from participation
in, and has not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any
such plan which could reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit
Guaranty Corporation or its successors or any other governmental agency.

 

5.9           Use
of Proceeds. Borrower shall use the proceeds of the Credit Extensions solely as working capital to fund its general business
requirements and not for personal, family, household or agricultural purposes.

 

5.10         Full
Disclosure. No written representation, warranty or other statement of Borrower in any certificate or written statement given
to Bank, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates
and written statements given to Bank, contains any untrue statement of a material fact or omits to state a material fact necessary
to make the statements contained in the certificates or statements not misleading (it being recognized by Bank that the projections
and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual
results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).

 

5.11         Definition
of “Knowledge.” For purposes of the Loan Documents, whenever a representation or warranty is made to Borrower’s
knowledge or awareness, to the “best of” Borrower’s knowledge, or with a similar qualification, knowledge or
awareness means the actual knowledge, after reasonable investigation, of any Responsible Officer.

 

    	 	11	 

     

    

 

		6	AFFIRMATIVE COVENANTS

 

Borrower shall do all
of the following:

 

6.1         Government
Compliance.

 

(a)          Maintain
its and all its Subsidiaries’ legal existence and good standing in their respective jurisdictions of formation and maintain
qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect
on Borrower’s business or operations. Borrower shall comply, and have each Subsidiary comply, in all material respects, with
all laws, ordinances and regulations to which it is subject.

 

(b)          Obtain
all of the Governmental Approvals necessary for the performance by Borrower of its obligations under the Loan Documents to which
it is a party and the grant of a security interest to Bank in the Collateral. Borrower shall promptly provide copies of any such
obtained Governmental Approvals to Bank.

 

6.2         Financial
Statements, Reports, Certificates. Provide Bank with the following:

 

(a)          Quarterly
Financial Statements. As soon as available, but no later than forty-five (45) days after the last day of each quarter (other
than with respect to the quarter ending at the end of Borrower’s fiscal year), a company prepared consolidated balance sheet
and income statement covering Parent’s and each of its Subsidiary’s operations for such quarter certified by a Responsible
Officer and in a form acceptable to Bank (the “Quarterly Financial Statements”);

 

(b)          Annual
Audited Financial Statements. As soon as available, and in any event within ninety (90) days following the end of Parent’s
fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified
opinion on the financial statements (provided however, that Borrower's unqualified opinion on financial statements may contain
a qualification as to going concern typical for venture backed companies similar to Borrower) from an independent certified public
accounting firm acceptable to Bank in its reasonable discretion (the “Annual Financial Statements”);

 

(c)          Compliance
Certificates. Within forty-five (45) days (or ninety (90) days with respect to the quarter ending at the end of Borrower’s
fiscal year) after the last day of each quarter and together with the Quarterly Financial Statements and, as appropriate, the Annual
Financial Statements, a duly completed Compliance Certificate signed by a Responsible Officer, certifying that as of the end of
such quarter, Borrower was in full compliance with all of the terms and conditions of this Agreement (except as noted therein),
and setting forth such other information as Bank may reasonably request;

 

(d)          Annual
Operating Budget and Financial Projections. Within thirty (30) days after the end of each fiscal year of Borrower (and more
frequently as updated), (i) annual operating budgets (including income statements, balance sheets and cash flow statements, by
month) for the following fiscal year of Borrower, and (ii) annual financial projections for the following fiscal year (on a quarterly
basis) as approved by Borrower’s board of directors, together with any related business forecasts used in the preparation
of such annual financial projections;

 

    	 	12	 

     

    

 

(e)          Other
Statements. Within five (5) days of delivery, copies of all statements, reports and notices made available to Borrower’s
security holders or to any holders of Subordinated Debt, in each case to the extent same have not been previously furnished to
the bank;

 

(f)          SEC
Filings. Within five (5) days of filing, copies of all periodic and other reports, proxy statements and other materials (in
each case to the extent material) filed by Borrower with the SEC, any Governmental Authority succeeding to any or all of the functions
of the SEC or with any national securities exchange, or distributed to its shareholders, as the case may be. Documents required
to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the
SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower
posts such documents, or provides a link thereto, on Borrower’s website on the Internet at Borrower’s website address;
provided, however, Borrower shall promptly notify Bank in writing (which may be by electronic mail) of the posting of any such
documents;

 

(g)          Legal
Action Notice. A prompt report of any legal actions pending or threatened in writing against Borrower or any of its Subsidiaries
that could result in damages or costs to Borrower or any of its Subsidiaries of, individually or in the aggregate, One Hundred
Thousand Dollars ($100,000) or more; and

 

(h)          Other
Financial Information. Other financial information reasonably requested by Bank.

 

6.3         Inventory;
Returns. Keep all Inventory in good and marketable condition, free from material defects. Returns and allowances between Borrower
and its Account Debtors shall follow Borrower’s customary practices as they exist at the Effective Date. Borrower must promptly
notify Bank of all returns, recoveries, disputes and claims that involve more than One Hundred Thousand Dollars ($100,000).

 

6.4         Taxes;
Pensions. Timely file, and require each of its Subsidiaries to timely file, all required tax returns and reports and timely
pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state and local taxes, assessments, deposits and
contributions owed by Borrower and each of its Subsidiaries, except for deferred payment of any taxes contested pursuant to the
terms of Section 5.8 hereof, and shall deliver to Bank, on demand, appropriate certificates attesting to such payments, and pay
all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms.

 

6.5         Insurance.

 

(a)          Keep
its business and the Collateral insured for risks and in amounts standard for companies in Borrower’s industry and location
and as Bank may reasonably request. Insurance policies shall be in a form, with financially sound and reputable insurance companies
that are not Affiliates of Borrower, and in amounts that are reasonably satisfactory to Bank. All property policies shall have
a lender’s loss payable endorsement showing Bank as lender loss payee. All liability policies shall show, or have endorsements
showing, Bank as an additional insured. Bank shall be named as lender loss payee and/or additional insured with respect to any
such insurance providing coverage in respect of any Collateral.

 

    	 	13	 

     

    

 

(b)          Proceeds
payable under any property policy are, at Bank’s option, payable to Bank on account of the Obligations. Notwithstanding the
foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrowers shall have the option of applying the proceeds
of any casualty policy up to One Hundred Thousand Dollars ($100,000.00) in the aggregate for all losses under all casualty policies
in any one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired
property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which
Bank has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of
Default, all proceeds payable under such casualty policy shall, at the option of Bank, be payable to Bank on account of the Obligations.

 

(c)          At
Bank’s request, Borrower shall deliver certified copies of insurance policies and evidence of all premium payments. Each
provider of any such insurance required under this Section 6.5 shall agree, by endorsement upon the policy or policies issued by
it or by independent instruments furnished to Bank, that it will give Bank thirty (30) days (or ten (10) days for nonpayment
of premium) prior (or, if the relevant insurance company confirms in writing that it does not customarily allow endorsement of
its policies to give such prior notice, concurrent) written notice before any such policy or policies shall be materially altered
or canceled. If Borrower fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any
required proof of payment to third persons and Bank, Bank may make all or part of such payment or obtain such insurance policies
required in this Section 6.5, and take any action under the policies Bank deems prudent.

 

6.6         Operating
Accounts.

 

(a)          Maintain
all of its operating and other deposit accounts and securities accounts with Bank and Bank’s Affiliates. Notwithstanding
anything to the contrary, Borrower shall be permitted to maintain its accounts with JP Morgan Chase as disclosed on the Perfection
Certificate delivered to Bank as of the Effective Date (the “Chase Accounts”) so long as the aggregate balance
in such accounts does not exceed Five Hundred Thousand Dollars ($500,000) at any time.

 

(b)          In
addition to and without limiting the restrictions in (a), Borrower shall provide Bank five (5) days prior written notice before
establishing any Collateral Account at or with any bank or financial institution other than Bank or Bank’s Affiliates. For
each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable bank or financial institution
(other than Bank) at or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate
instrument with respect to such Collateral Account to perfect Bank’s Lien in such Collateral Account in accordance with the
terms hereunder, which control agreements may not be terminated without the prior written consent of Bank. The provisions of the
previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit
payments to or for the benefit of Borrower’s employees and identified to Bank by Borrower as such.

 

6.7         Reserved.

  

    	 	14	 

     

    

  

6.8         Protection
of Intellectual Property Rights.

 

(a)        (i)
Undertake commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property
material to the Borrower’s business; (ii) promptly advise Bank in writing of material infringements or any other event that
could reasonably be expected to materially and adversely affect the value of its Intellectual Property; and (iii) not allow any
Intellectual Property material to Borrower’s business to be abandoned, forfeited or dedicated to the public without Bank’s
written consent.

 

(b)          Provide
written notice to Bank within twenty (20) days of entering or becoming bound by any Restricted License (other than over-the-counter
software that is commercially available to the public). Borrower shall take such commercially reasonable steps as Bank requests
to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (i) any Restricted License to
be deemed “Collateral” and for Bank to have a security interest in it that might otherwise be restricted or prohibited
by law or by the terms of any such Restricted License, whether now existing or entered into in the future, and (ii) Bank to
have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Bank’s
rights and remedies under this Agreement and the other Loan Documents.

 

6.9         Litigation
Cooperation. From the date hereof and continuing through the termination of this Agreement, make available to Bank, without
expense to Bank, Borrower and its officers, employees and agents and Borrower’s books and records, to the extent that Bank
may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Bank with
respect to any Collateral or relating to Borrower.

 

6.10       Access
to Collateral; Books and Records. Allow Bank, or its agents, at reasonable times, on two (2) Business Day’s notice (provided
no notice is required if an Event of Default has occurred and is continuing), to inspect the Collateral and audit and copy Borrower’s
Books. Such inspections or audits shall be conducted no more often than once every twelve (12) months unless an Event of Default
has occurred and is continuing in which case such inspections and audits shall occur as often as Bank shall determine is necessary.
The foregoing inspections and audits shall be at Borrower’s expense. In the event Borrower and Bank schedule an audit more
than ten (10) days in advance, and Borrower cancels or seeks to reschedule the audit with less than ten (10) days written notice
to Bank, then (without limiting any of Bank’s rights or remedies), Borrower shall pay Bank a fee of One Thousand Dollars
($1,000) plus any out-of-pocket expenses incurred by Bank to compensate Bank for the anticipated costs and expenses of the cancellation
or rescheduling.

 

    	 	15	 

     

    

 

6.11         Formation
or Acquisition of Subsidiaries. Notwithstanding and without limiting the negative covenants contained in Section 7.3 and 7.7
hereof, at the time that Borrower forms any direct or indirect Subsidiary or acquires any direct or indirect Subsidiary after the
Effective Date, Borrower shall (a) cause such new Subsidiary to provide to Bank a joinder to this Agreement to cause such Subsidiary
to become a co-borrower hereunder together with such appropriate financing statements and/or Control Agreements, all in form and
substance reasonably satisfactory to Bank (including being sufficient to grant Bank a first priority Lien (subject to Permitted
Liens) in and to the assets of such newly formed or acquired Subsidiary), (b) provide to Bank appropriate certificates and powers
and financing statements, pledging all of the direct or beneficial ownership interest in such new Subsidiary, in form and substance
satisfactory to Bank, and (c) provide to Bank all other documentation in form and substance satisfactory to Bank, including one
or more opinions of counsel satisfactory to Bank, which in its opinion is appropriate with respect to the execution and delivery
of the applicable documentation referred to above. Any document, agreement, or instrument executed or issued pursuant to this Section
6.13 shall be a Loan Document. Notwithstanding anything to the contrary, in no event shall (a) any Foreign Subsidiary be required
to become a Borrower or Guarantor hereunder or to grant a Lien in its assets or (b) more than 65% of the presently existing and
hereafter arising issued and outstanding shares of capital stock owned by Borrower of any Foreign Subsidiary which shares entitle
the holder thereof to vote for directors or any other matter be pledged, in each case to the extent that same would cause any Borrower
adverse tax consequences under Internal Revenue Code Section 956 or any successor statute during the subject fiscal year.

 

6.12         Further
Assurances. Execute any further instruments and take further action as Bank reasonably requests to perfect or continue Bank’s
Lien in the Collateral or to effect the purposes of this Agreement.

 

6.13         Financial
Trigger. From and at all times after the Financial Trigger Event but prior to the Financial Trigger Release Event, Borrower
shall deliver to and maintain with Bank, Pledged Collateral in an amount of not less than the Minimum Cash Collateral Value.

 

    	 	16	 

     

    

 

		7	NEGATIVE COVENANTS

 

Borrower shall not
do any of the following without Bank’s prior written consent:

 

7.1         Dispositions.
Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively, “Transfer”), or permit any of
its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary
course of business; (b) of worn-out or obsolete Equipment that is, in the reasonable judgment of Borrower, no longer economically
practicable to maintain or useful in the ordinary course of business of Borrower; (c) consisting of Permitted Liens and Permitted
Investments; (d) consisting of the sale or issuance of any stock of Borrower permitted under Section 7.2 of this Agreement;
(e) consisting of Borrower’s use or transfer of money or Cash Equivalents in a manner that is not prohibited by the terms
of this Agreement or the other Loan Documents; (f) of non-exclusive licenses for the use of the property of Borrower or its Subsidiaries
in the ordinary course of business and licenses that could not result in a legal transfer of title of the licensed property but
that may be exclusive in respects other than territory and that may be exclusive as to territory only as to discreet geographical
areas, (g) transfers of assets among Borrowers or Subsidiaries that are secured Guarantors, (h) transfers of assets in an aggregate
amount not to exceed One Hundred Thousand Dollars ($100,000) in any fiscal year (A) by Borrowers to their Subsidiaries that are
not Borrowers or secured Guarantors hereunder and (B) by Subsidiaries that are not Borrowers or secured Guarantors hereunder to
other Subsidiaries that are not Borrowers or secured Guarantors hereunder or to a Borrower; and (i) so long as no Event of Default
has occurred and is continuing, other dispositions of assets (other than Intellectual Property) not otherwise permitted by this
Section 7.1 with a fair market value not to exceed One Hundred Thousand Dollars ($100,000.00) in the aggregate in any fiscal year.

 

7.2         Changes
in Business, Management, Control or Business Locations.

 

(a)          Engage
in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower and such
Subsidiary, as applicable, or reasonably related thereto; (b) liquidate or dissolve; (c) fail to provide notice to Bank of
any Key Person departing from or ceasing to be employed by Borrower within five (5) Business Days after such Key Person’s
departure from Borrower; or (d)  permit or suffer any Change in Control.

 

Borrower shall not, without
at least thirty (30) days prior written notice to Bank: (1) add any new offices or business locations, including warehouses (unless
such new offices or business locations contain less than One Hundred Thousand Dollars ($100,000) in Borrower’s assets or
property) or deliver any portion of the Collateral valued, individually or in the aggregate, in excess of One Hundred Thousand
Dollars ($100,000) to a bailee at a location other than to a bailee and at a location already disclosed in the Perfection Certificate,
(2) change its jurisdiction of organization, (3) change its organizational structure or type, (4) change its legal name, or (5)
change any organizational number (if any) assigned by its jurisdiction of organization. If Borrower intends to deliver any portion
of the Collateral valued, individually or in the aggregate, in excess of One Hundred Thousand Dollars ($100,000) to a bailee, and
Bank and such bailee are not already parties to a bailee agreement governing both the Collateral and the location to which Borrower
intends to deliver the Collateral, then Borrower will first receive the written consent of Bank, and such bailee shall execute
and deliver a bailee agreement in form and substance satisfactory to Bank.

 

    	 	17	 

     

    

 

7.3           Mergers
or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or
acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person
(including, without limitation, by the formation of any Subsidiary), except for Subsidiaries formed in accordance with Section
6.11. Notwithstanding anything to the contrary, a Subsidiary may merge or consolidate into another Subsidiary or into Borrower.

 

7.4           Indebtedness.
Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.

 

7.5           Encumbrance.
Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the
sale of any Accounts, or permit any of its Subsidiaries to do so, in each case except for Permitted Liens; permit any Collateral
not to be subject to the first priority security interest granted herein (which Collateral may be subject to Permitted Liens);
or enter into any agreement, document, instrument or other arrangement (except with or in favor of Bank) with any Person that directly
or indirectly prohibits, or has the effect of prohibiting, Borrower from assigning, mortgaging, pledging, granting a security interest
in or upon, or encumbering any of Borrower’s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof
and the definition of “Permitted Lien” herein.

 

7.6           Maintenance
of Collateral Accounts. Maintain any Collateral Account except pursuant to the terms of Section 6.6(b) hereof.

 

7.7           Distributions;
Investments. (a) Pay any dividends or make any distribution or payment or redeem, retire or purchase any capital stock or other
equity interests, except (i) any Borrower may pay dividends or distributions to any other Borrower, (ii) any Borrower may pay dividends
solely in common stock; and (iii) any Borrower may repurchase the stock of former employees or consultants pursuant to stock repurchase
agreements so long as an Event of Default does not exist at the time of such repurchase and would not exist after giving effect
to such repurchase, provided that the aggregate amount of all such repurchases does not exceed One Hundred Thousand Dollars ($100,000)
per fiscal year; or (b) directly or indirectly make any Investment (including, without limitation, by the formation of any Subsidiary,
except for Subsidiaries formed in accordance with Section 6.11) other than Permitted Investments, or permit any of its Subsidiaries
to do so.

 

7.8           Transactions
with Affiliates. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower,
except for (a) transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are
no less favorable to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person, (b) bona
fide equity financings with Borrower’s investors; (c) transactions with Affiliates that are borrowers or secured guarantors
hereunder; (d) Investments described in clauses (f), (g), (h) and (i) of the definition of Permitted Investments; (e) reasonable
and customary director and officer compensation (including bonuses and stock option programs), benefits and indemnification arrangements,
in the ordinary course of business and approved by the board of directors or other equivalent governing body of Borrower (or a
committee thereof); and (f) transactions described under the heading “Related Party Transactions” set forth in the
Parent’s Form 10-K Report filed with the Securities and Exchange Commissions for the period ended December 31, 2016.

 

    	 	18	 

     

    

 

7.9           Subordinated
Debt.

 

(a)          Make
or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or other similar agreement
to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt that
would increase the amount thereof, provide for earlier or greater principal, interest, or other payments thereon, or adversely
affect the subordination thereof to Obligations owed to Bank (except as otherwise provided for by the terms of the subordination
agreement, intercreditor agreement or similar agreement relating to such Subordinated Debt).

 

7.10         Compliance.
Become an “investment company” or a company controlled by an “investment company”, under the Investment
Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock
(as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension
for that purpose; fail to (a) meet the minimum funding requirements of ERISA, (b) prevent a Reportable Event or Prohibited Transaction,
as defined in ERISA, from occurring, or (c) comply with the Federal Fair Labor Standards Act, the failure of any of the conditions
described in clauses (a) through (c) which could reasonably be expected to have a material adverse effect on Borrower’s business;
or violate any other law or regulation, if the violation could reasonably be expected to have a material adverse effect on Borrower’s
business, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from participation in, permit
partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing
and deferred compensation plan which could reasonably be expected to result in any liability of Borrower, including any liability
to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency.

 

7.11         Financial
Trigger Event. From and at all times after the Financial Trigger Event but prior to the Financial Trigger Release Event, allow,
permit or otherwise suffer the value of Pledged Collateral to be less than the Minimum Cash Collateral Value at any time.

 

		8	EVENTS OF DEFAULT

 

Any one of the following
shall constitute an event of default (an “Event of Default”) under this Agreement:

 

8.1           Payment
Default. Borrower fails to (a) make any payment of principal or interest on any Credit Extension when due, or (b) pay
any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace
period shall not apply to payments due on the Growth Capital Maturity Date). During the cure period, the failure to make or pay
any payment specified in clause (b) hereunder is not an Event of Default (but no Credit Extension will be made during the cure
period);

 

    	 	19	 

     

    

 

8.2         Covenant
Default.

 

(a)          Borrower
fails or neglects to perform any obligation in Sections 6.2, 6.4, 6.5, 6.6, 6.7, 6.8, 6.10, 6.11, or 6.13 or violates any covenant
in Section 7; or

 

(b)          Borrower
fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement
or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition,
covenant or agreement that can be cured, has failed to cure the default within ten (10) days after the occurrence thereof; provided,
however, that if the default cannot by its nature be cured within the ten (10) day period or cannot after diligent attempts by
Borrower be cured within such ten (10) day period, and such default is likely to be cured within a reasonable time, then Borrower
shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within
such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall
be made during such cure period). Cure periods provided under this section shall not apply, among other things, to financial covenants
or any other covenants set forth in clause (a) above;

 

8.3         Material
Adverse Change. A Material Adverse Change occurs;

 

8.4         Attachment;
Levy; Restraint on Business.

 

(a) (i) The service of
process seeking to attach, by trustee or similar process, any funds of Borrower or of any entity under the control of Borrower
(including a Subsidiary) in excess of Fifty Thousand Dollars ($50,000), or (ii) a notice of lien or levy is filed against any of
Borrower’s assets by any Governmental Authority, and the same under subclauses (i) and (ii) hereof are not, within ten (10)
days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however,
no Credit Extensions shall be made during any ten (10) day cure period; or

 

(b) (i) any material
portion of Borrower’s assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any
court order enjoins, restrains, or prevents Borrower from conducting all or any material part of its business;

 

8.5         Insolvency.
(a) Borrower is unable to pay its debts (including trade debts) as they become due or otherwise becomes insolvent; (b) Borrower
begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower and not dismissed or stayed within forty-five
(45) days (but no Credit Extensions shall be made while any of the conditions described in clause (a) exist and/or until any Insolvency
Proceeding is dismissed);

 

8.6         Other
Agreements. There is, under any agreement to which Borrower is a party with a third party or parties, (a) any default resulting
in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount
individually or in the aggregate in excess of One Hundred Thousand Dollars ($100,000); or (b) any breach or default by Borrower
or Guarantor, the result of which could have a material adverse effect on Borrower’s or any Guarantor’s business;

 

    	 	20	 

     

    

 

8.7           Judgments;
Penalties. One or more fines, penalties or final judgments, orders, or decrees for the payment of money in an amount, individually
or in the aggregate, of at least One Hundred Thousand Dollars ($100,000) (or, as to judgments relating to litigation disclosed
in the Perfection Certificate as of the Effective Date, an aggregate amount of One Million Two Hundred Fifty Thousand Dollars ($1,250,000)
for all such disclosed litigation, subject to the condition that Borrower provides notice to Bank of such a judgment no later than
five (5) Business Days after it is entered) (not covered by independent third-party insurance as to which liability has been accepted
by such insurance carrier) shall be rendered against Borrower by any Governmental Authority, and the same are not, within ten (10)
days after the entry, assessment or issuance thereof, discharged, satisfied, or paid, or after execution thereof stayed or bonded
pending appeal, or such judgments are not discharged prior to the expiration of any such stay (provided that no Credit Extensions
will be made prior to the satisfaction, payment, discharge, stay, or bonding of such fine, penalty, judgment, order, or decree);

 

8.8           Misrepresentations.
Borrower or any Person acting for Borrower makes any representation, warranty or other statement now or later in this Agreement,
any Loan Document or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan Document, and such
representation, warranty, or other statement is incorrect in any material respect when made;

 

8.9           Subordinated
Debt. A default or breach occurs under any agreement between Borrower and any creditor of Borrower that signed a subordination,
intercreditor, or other similar agreement with Bank, or any creditor that has signed such an agreement with Bank breaches any terms
of such agreement; or

 

8.10         Delisting.
The shares of common stock of Parent are delisted from the NASDAQ because of failure to comply with continued listing standards
thereof or due to a voluntary delisting which results in such shares not being listed on any other nationally recognized stock
exchange in the United States having listing standards at least as restrictive as the NASDAQ; or

 

8.11         Governmental
Approvals. Any Governmental Approval required pursuant to any Loan Document or the operation of the Borrower’s business
shall have been (a) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the ordinary course for
a full term or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications
for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of the actions described
in clause (a) above, and such decision or such revocation, rescission, suspension, modification or non-renewal (i) causes, or could
reasonably be expected to cause, a Material Adverse Change, or (ii) adversely affects the legal qualifications of Borrower
or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension,
modification or non-renewal could reasonably be expected to affect the status of or legal qualifications of Borrower or any of
its Subsidiaries to hold any Governmental Approval in any other jurisdiction.

 

    	 	21	 

     

    

 

		9	BANK’S RIGHTS AND REMEDIES

 

9.1         Rights
and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may, without notice or demand, do
any or all of the following:

 

(a)          declare
all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations are immediately
due and payable without any action by Bank);

 

(b)          stop
advancing money or extending credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower
and Bank;

 

(c)          for
any Letters of Credit, demand that Borrower (i) deposit cash with Bank in an amount equal to at least 105% (110% for Letters of
Credit denominated in a Foreign Currency) of the Dollar Equivalent of the aggregate face amount of all Letters of Credit remaining
undrawn (plus all interest, fees, and costs due or to become due in connection therewith (as estimated by Bank in its good faith
business judgment)), to secure all of the Obligations relating to such Letters of Credit, as collateral security for the repayment
of any future drawings under such Letters of Credit, and Borrower shall forthwith deposit and pay such amounts, and (ii) pay
in advance all letter of credit fees scheduled to be paid or payable over the remaining term of any Letters of Credit;

 

(d)          terminate
any FX Contracts;

 

(e)          verify
the amount of, demand payment of and performance under, and collect any Accounts and General Intangibles, settle or adjust disputes
and claims directly with Account Debtors for amounts on terms and in any order that Bank considers advisable, notify any Person
owing Borrower money of Bank’s security interest in such funds;

 

(f)          make
any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the
Collateral. Borrower shall assemble the Collateral if Bank requests and make it available as Bank designates. Bank may enter premises
where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise
any Lien that appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Bank a license
to enter and occupy any of its premises, without charge, to exercise any of Bank’s rights or remedies;

 

(g)          apply
to the Obligations (i) any balances and deposits of Borrower it holds, or (ii) any amount held by Bank owing to or for the credit
or the account of Borrower;

 

(h)          ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale and sell the Collateral. Bank is hereby
granted a non-exclusive, royalty-free license or other right to, upon and during the continuation of an Event of Default, use,
without charge, Borrower’s labels, Patents, Copyrights, mask works, rights of use of any name, trade secrets, trade names,
Trademarks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising
for sale, and selling any Collateral and, in connection with Bank’s exercise of its rights under this Section, Borrower’s
rights under all licenses and all franchise agreements inure to Bank’s benefit;

 

(i)          place
a “hold” on any account maintained with Bank and/or deliver a notice of exclusive control, any entitlement order, or
other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;

 

    	 	22	 

     

    

 

(j)          demand
and receive possession of Borrower’s Books; and

 

(k)          exercise
all rights and remedies available to Bank under the Loan Documents or at law or equity, including all remedies provided under the
Code (including disposal of the Collateral pursuant to the terms thereof).

 

9.2         Power
of Attorney. Borrower hereby irrevocably appoints Bank as its lawful attorney-in-fact, exercisable upon the occurrence and
during the continuance of an Event of Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or
security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c)
settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Bank determines
reasonable; (d) make, settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien,
charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise
take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Bank or a third party as the
Code permits. Borrower hereby appoints Bank as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary
to perfect or continue the perfection of Bank’s security interest in the Collateral, regardless of whether an Event of Default
has occurred, until all Obligations have been satisfied in full and Bank is under no further obligation to make Credit Extensions
hereunder. Bank’s foregoing appointment as Borrower’s attorney in fact, and all of Bank’s rights and powers,
coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Bank’s obligation
to provide Credit Extensions terminates.

 

9.3         Protective
Payments. If Borrower fails to obtain the insurance called for by Section 6.5 or fails to pay any premium thereon or fails
to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required
to preserve the Collateral, Bank may obtain such insurance or make such payment, and all amounts so paid by Bank are Bank Expenses
and immediately due and payable, bearing interest at the then highest rate applicable to the Obligations, and secured by the Collateral.
Bank will make reasonable efforts to provide Borrower with notice of Bank obtaining such insurance at the time it is obtained or
within a reasonable time thereafter. No payments by Bank are deemed an agreement to make similar payments in the future or Bank’s
waiver of any Event of Default.

 

9.4         Application
of Payments and Proceeds Upon Default. If an Event of Default has occurred and is continuing, Bank shall have the right to
apply in any order any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result
of any collection of Accounts or other disposition of the Collateral, or otherwise, to the Obligations. Bank shall pay any surplus
to Borrower by credit to the Designated Deposit Account or to other Persons legally entitled thereto; Borrower shall remain liable
to Bank for any deficiency. If Bank, directly or indirectly, enters into a deferred payment or other credit transaction with any
purchaser at any sale of Collateral, Bank shall have the option, exercisable at any time, of either reducing the Obligations by
the principal amount of the purchase price or deferring the reduction of the Obligations until the actual receipt by Bank of cash
therefor.

 

    	 	23	 

     

    

 

9.5         Bank’s
Liability for Collateral. So long as Bank complies with reasonable banking practices regarding the safekeeping of the Collateral
in the possession or under the control of Bank, Bank shall not be liable or responsible for: (a) the safekeeping of the Collateral;
(b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier,
warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or destruction of the Collateral.

 

9.6         No
Waiver; Remedies Cumulative. Bank’s failure, at any time or times, to require strict performance by Borrower of any provision
of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Bank thereafter to demand strict
performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by the party granting the
waiver and then is only effective for the specific instance and purpose for which it is given. Bank’s rights and remedies
under this Agreement and the other Loan Documents are cumulative. Bank has all rights and remedies provided under the Code, by
law, or in equity. Bank’s exercise of one right or remedy is not an election and shall not preclude Bank from exercising
any other remedy under this Agreement or other remedy available at law or in equity, and Bank’s waiver of any Event of Default
is not a continuing waiver. Bank’s delay in exercising any remedy is not a waiver, election, or acquiescence.

 

9.7         Demand
Waiver. Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment
at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees
held by Bank on which Borrower is liable.

 

		10	NOTICES

 

All notices, consents,
requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing
and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business
Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid;
(b) upon transmission, when sent by electronic mail or facsimile transmission; (c) one (1) Business Day after deposit with a reputable
overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed
to the party to be notified and sent to the address, facsimile number, or email address indicated below. Bank or Borrower may change
its mailing or electronic mail address or facsimile number by giving the other party written notice thereof in accordance with
the terms of this Section 10.

 

	If to Borrower:	Lipocine Inc.
	 	675 Arapeen Drive, Suite 202
	 	Salt Lake City, UT 84108
	 	Attn:  Chief Financial Officer
	 	Fax:  (801) 994-7388
	 	Email:  mb@lipocine.com
	 	Website URL: https://www.lipocine.com/
	 	 
	If to Bank:	Silicon Valley Bank 
	 	4370 La Jolla Village Drive, Suite 1050
	 	San Diego, CA 92122
	 	Attn: Igor DaCruz
	 	Fax:  (858) 622-1424
	 	Email:  IDacruz@svb.com

 

    	 	24	 

     

    

 

		11	CHOICE OF LAW, VENUE, JURY TRIAL WAIVER AND JUDICIAL REFERENCE

 

Except as otherwise
expressly provided in any of the Loan Documents, California law governs the Loan Documents without regard to principles of conflicts
of law. Borrower and Bank each submit to the exclusive jurisdiction of the State and Federal courts in Santa Clara County, California;
provided, however, that nothing in this Agreement shall be deemed to operate to preclude Bank from bringing suit or taking other
legal action in any other jurisdiction to realize on the Collateral or any other security for the Obligations, or to enforce a
judgment or other court order in favor of Bank. Borrower expressly submits and consents in advance to such jurisdiction in any
action or suit commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of personal
jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as
is deemed appropriate by such court. Borrower hereby waives personal service of the summons, complaints, and other process issued
in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified
mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section 10 of
this Agreement and that service so made shall be deemed completed upon the earlier to occur of Borrower’s actual receipt
thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid.

 

TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, BORROWER AND BANK EACH WAIVE THEIR RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING
OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY
AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED
THIS WAIVER WITH ITS COUNSEL.

 

WITHOUT INTENDING IN
ANY WAY TO LIMIT THE PARTIES’ AGREEMENT TO WAIVE THEIR RESPECTIVE RIGHT TO A TRIAL BY JURY, if the above waiver of the right
to a trial by jury is not enforceable, the parties hereto agree that any and all disputes or controversies of any nature between
them arising at any time shall be decided by a reference to a private judge, mutually selected by the parties (or, if they cannot
agree, by the Presiding Judge of the Santa Clara County, California Superior Court) appointed in accordance with California Code
of Civil Procedure Section 638 (or pursuant to comparable provisions of federal law if the dispute falls within the exclusive jurisdiction
of the federal courts), sitting without a jury, in Santa Clara County, California; and the parties hereby submit to the jurisdiction
of such court. The reference proceedings shall be conducted pursuant to and in accordance with the provisions of California Code
of Civil Procedure §§ 638 through 645.1, inclusive. The private judge shall have the power, among others, to grant provisional
relief, including without limitation, entering temporary restraining orders, issuing preliminary and permanent injunctions and
appointing receivers. All such proceedings shall be closed to the public and confidential and all records relating thereto shall
be permanently sealed. If during the course of any dispute, a party desires to seek provisional relief, but a judge has not been
appointed at that point pursuant to the judicial reference procedures, then such party may apply to the Santa Clara County, California
Superior Court for such relief. The proceeding before the private judge shall be conducted in the same manner as it would be before
a court under the rules of evidence applicable to judicial proceedings. The parties shall be entitled to discovery which shall
be conducted in the same manner as it would be before a court under the rules of discovery applicable to judicial proceedings.
The private judge shall oversee discovery and may enforce all discovery rules and orders applicable to judicial proceedings in
the same manner as a trial court judge. The parties agree that the selected or appointed private judge shall have the power to
decide all issues in the action or proceeding, whether of fact or of law, and shall report a statement of decision thereon pursuant
to California Code of Civil Procedure § 644(a). Nothing in this paragraph shall limit the right of any party at any time to
exercise self-help remedies, foreclose against collateral, or obtain provisional remedies. The private judge shall also determine
all issues relating to the applicability, interpretation, and enforceability of this paragraph.

 

    	 	25	 

     

    

 

This Section 11 shall
survive the termination of this Agreement.

 

		12	GENERAL PROVISIONS

 

12.1         Termination
Prior to Maturity Date; Survival. All covenants, representations and warranties made in this Agreement continue in full force until
this Agreement has terminated pursuant to its terms and all Obligations have been satisfied. So long as Borrower has satisfied
the Obligations (other than inchoate indemnity obligations, any other obligations which, by their terms, are to survive the termination
of this Agreement, and any Obligations under Bank Services Agreements that are cash collateralized in accordance with Section 4.1
of this Agreement), this Agreement may be terminated prior to the Growth Capital Maturity Date by Borrower, in accordance with
Section 2.1.1(c). Those obligations that are expressly specified in this Agreement as surviving this Agreement’s termination
shall continue to survive notwithstanding this Agreement’s termination.

 

12.2         Successors
and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may
not assign this Agreement or any rights or obligations under it without Bank’s prior written consent (which may be granted
or withheld in Bank’s discretion). Bank has the right, without the consent of or notice to Borrower, to sell, transfer, assign,
negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations, rights, and benefits under
this Agreement and the other Loan Documents.

 

12.3         Indemnification.
Borrower agrees to indemnify, defend and hold Bank and its directors, officers, employees, agents, attorneys, or any other Person
affiliated with or representing Bank (each, an “Indemnified Person”) harmless against: (i) all obligations,
demands, claims, and liabilities (collectively, “Claims”) claimed or asserted by any other party in connection
with the transactions contemplated by the Loan Documents; and (ii) all losses or expenses (including Bank Expenses) in any way
suffered, incurred, or paid by such Indemnified Person as a result of, following from, consequential to, or arising from transactions
between Bank and Borrower (including reasonable attorneys’ fees and expenses), except for Claims and/or losses directly caused
by such Indemnified Person’s gross negligence or willful misconduct.

 

    	 	26	 

     

    

 

This Section 12.3 shall
survive until all statutes of limitation with respect to the Claims, losses, and expenses for which indemnity is given shall have
run.

 

12.4         Time
of Essence. Time is of the essence for the performance of all Obligations in this Agreement.

 

12.5         Severability
of Provisions. Each provision of this Agreement is severable from every other provision in determining the enforceability of
any provision.

 

12.6         Correction
of Loan Documents. Bank may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents consistent
with the agreement of the parties.

 

12.7         Amendments
in Writing; Waiver; Integration. No purported amendment or modification of any Loan Document, or waiver, discharge or termination
of any obligation under any Loan Document, shall be enforceable or admissible unless, and only to the extent, expressly set forth
in a writing signed by the party against which enforcement or admission is sought. Without limiting the generality of the foregoing,
no oral promise or statement, nor any action, inaction, delay, failure to require performance or course of conduct shall operate
as, or evidence, an amendment, supplement or waiver or have any other effect on any Loan Document. Any waiver granted shall be
limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether
similar or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver. The Loan Documents
represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements,
understandings, representations, warranties, and negotiations between the parties about the subject matter of the Loan Documents
merge into the Loan Documents.

 

12.8         Counterparts.
This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which,
when executed and delivered, is an original, and all taken together, constitute one Agreement.

 

12.9         Borrower
Liability. Each Borrower may, acting singly, request Credit Extensions hereunder. Each Borrower hereby appoints the other as
agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder. Each Borrower
hereunder shall be jointly and severally obligated to repay all Obligations, including, without limitation, all Credit Extensions
made hereunder, regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received
all Credit Extensions. Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable
law, including, without limitation, the benefit of California Civil Code Section 2815 permitting revocation as to future transactions
and the benefit of California Civil Code Sections 1432, 2809, 2810, 2819, 2839, 2845, 2847, 2848, 2849, 2850, and 2899 and 3433,
and (b) any right to require Bank to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any
security; or (iii) pursue any other remedy. Bank may exercise or not exercise any right or remedy it has against any Borrower or
any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower’s
liability. Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all
rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Bank
under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any
other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with
respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or
to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations
in connection with this Agreement or otherwise. Any agreement providing for indemnification, reimbursement or any other arrangement
prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such
Borrower shall hold such payment in trust for Bank and such payment shall be promptly delivered to Bank for application to the
Obligations, whether matured or unmatured.

 

    	 	27	 

     

    

 

12.10         Confidentiality.
In handling any confidential information, Bank shall exercise the same degree of care that it exercises for its own proprietary
information, but disclosure of information may be made: (a) to Bank’s Subsidiaries or Affiliates (such Subsidiaries
and Affiliates, together with Bank, collectively, “Bank Entities”); (b) to prospective transferees or purchasers
of any interest in the Credit Extensions (provided, however, that any prospective transferee or purchaser shall have entered into
an agreement containing provisions substantially the same as those in this Section); (c) as required by law, regulation, subpoena,
or other order; (d) to Bank’s regulators or as otherwise required in connection with Bank’s examination or audit;
(e) as Bank considers appropriate in exercising remedies under the Loan Documents; and (f) to third-party service providers
of Bank so long as such service providers have executed a confidentiality agreement with Bank with terms no less restrictive than
those contained herein. Confidential information does not include information that is either: (i) in the public domain or
in Bank’s possession when disclosed to Bank, or becomes part of the public domain (other than as a result of its disclosure
by Bank in violation of this Agreement) after disclosure to Bank; or (ii) disclosed to Bank by a third party if Bank does not know
that the third party, is prohibited from disclosing the information.

 

Bank Entities may use
anonymous forms of confidential information for aggregate datasets, for analyses or reporting, and for any other uses not expressly
prohibited in writing by Borrower. The provisions of the immediately preceding sentence shall survive termination of this Agreement.

 

12.11         Attorneys’
Fees, Costs and Expenses. In any action or proceeding between Borrower and Bank arising out of or relating to the Loan Documents,
the prevailing party shall be entitled to recover its reasonable attorneys’ fees and other costs and expenses incurred, in
addition to any other relief to which it may be entitled.

 

12.12         Electronic
Execution of Documents. The words “execution,” “signed,” “signature” and words of like
import in any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form, each
of which shall be of the same legal effect, validity and enforceability as a manually executed signature or the use of a paper-based
recordkeeping systems, as the case may be, to the extent and as provided for in any applicable law, including, without limitation,
any state law based on the Uniform Electronic Transactions Act.

 

    	 	28	 

     

    

 

12.13         Captions.
The headings used in this Agreement are for convenience only and shall not affect the interpretation of this Agreement.

 

12.14         Construction
of Agreement. The parties mutually acknowledge that they and their attorneys have participated in the preparation and negotiation
of this Agreement. In cases of uncertainty this Agreement shall be construed without regard to which of the parties caused the
uncertainty to exist.

 

12.15         Relationship.
The relationship of the parties to this Agreement is determined solely by the provisions of this Agreement. The parties do not
intend to create any agency, partnership, joint venture, trust, fiduciary or other relationship with duties or incidents different
from those of parties to an arm’s-length contract.

 

12.16         Third
Parties. Nothing in this Agreement, whether express or implied, is intended to: (a) confer any benefits, rights or remedies
under or by reason of this Agreement on any persons other than the express parties to it and their respective permitted successors
and assigns; (b) relieve or discharge the obligation or liability of any person not an express party to this Agreement; or (c)
give any person not an express party to this Agreement any right of subrogation or action against any party to this Agreement.

 

		13	DEFINITIONS

 

13.1         Definitions.
As used in the Loan Documents, the word “shall” is mandatory, the word “may” is permissive, the word “or”
is not exclusive, the words “includes” and “including” are not limiting, the singular includes the plural,
and numbers denoting amounts that are set off in brackets are negative. As used in this Agreement, the following capitalized terms
have the following meanings:

 

“Account”
is any “account” as defined in the Code with such additions to such term as may hereafter be made, and includes, without
limitation, all accounts receivable and other sums owing to Borrower.

 

“Account Debtor”
is any “account debtor” as defined in the Code with such additions to such term as may hereafter be made.

 

“Affiliate”
is, with respect to any Person, each other Person that owns or controls directly or indirectly the Person, any Person that controls
or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors,
partners and, for any Person that is a limited liability company, that Person’s managers and members.

 

“Agreement”
is defined in the preamble hereof.

 

“Bank”
is defined in the preamble hereof.

 

    	 	29	 

     

    

 

“Bank Entities”
is defined in Section 12.10.

 

“Bank Expenses”
are all audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and expenses) for preparing, amending,
negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection
with appeals or Insolvency Proceedings and those identified as Bank Expenses in Section 9.3 hereof) or otherwise incurred with
respect to Borrower.

 

“Bank Services” 
are any products, credit services, and/or financial accommodations previously, now, or hereafter provided to Borrower or any of
its Subsidiaries by Bank or any Bank Affiliate, including, without limitation, any letters of credit, cash management services
(including, without limitation, merchant services, direct deposit of payroll, business credit cards, and check cashing services),
interest rate swap arrangements, and foreign exchange services as any such products or services may be identified in Bank’s
various agreements related thereto (each, a “Bank Services Agreement”).

 

“Borrower”
is defined in the preamble hereof.

 

“Borrower’s
Books” are all Borrower’s books and records including ledgers, federal and state tax returns, records regarding
Borrower’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or
storage or any equipment containing such information.

 

“Borrowing
Resolutions” are, with respect to any Person, those resolutions substantially in the form attached hereto as Exhibit
C.

 

“Business
Day” is any day that is not a Saturday, Sunday or a day on which Bank is closed.

 

“Cash Equivalents”
means (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State
thereof having maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more
than one (1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s
Investors Service, Inc.; (c) Bank’s certificates of deposit issued maturing no more than one (1) year after issue; and (d)
money market funds at least ninety-five percent (95%) of the assets of which constitute Cash Equivalents of the kinds described
in clauses (a) through (c) of this definition.

 

“Change in
Control” means (a) at any time after the date hereof, any “person” or “group” (as such terms
are used in Sections 13(d) and 14(d) of the Exchange Act) shall become, or obtain rights (whether by means of warrants, options
or otherwise) to become, the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act) that
is not a holder of equity securities of Parent on the date hereof, directly or indirectly, of twenty-five percent (25%) or more
of the ordinary voting power for the election of directors of Parent (determined on a fully diluted basis) other than by the sale
of Parent’s equity securities in a public offering or to venture capital or private equity investors so long as Borrower
identifies to Bank the venture capital or private equity investors at least seven (7) Business Days prior to the closing of the
transaction and provides to Bank a description of the material terms of the transaction; (b) during any period of 12
consecutive months after the date hereof, a majority of the members of the Board of Directors or other equivalent governing body
of Parent cease to be composed of individuals (i) who were members of that Board or equivalent governing body on the first
day of such period, (ii) whose election or nomination to that Board or equivalent governing body was approved or accepted
by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority
of that Board or equivalent governing body or (iii) whose election or nomination to that Board or other equivalent governing
body was approved or accepted by individuals referred to in clauses (i) and (ii) above constituting at the time of such
election or nomination at least a majority of that Board or equivalent governing body; or (c) at any time, Borrower shall
cease to own and control, of record and beneficially, directly or indirectly, one hundred percent (100%) of each class of outstanding
capital stock of each Subsidiary of Borrower free and clear of all Liens (except Liens created by this Agreement).

 

    	 	30	 

     

    

 

“Claims”
is defined in Section 12.3.

 

“Code”
is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of California; provided,
that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently
in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; provided
further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority
of, or remedies with respect to, Bank’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a
jurisdiction other than the State of California, the term “Code” shall mean the Uniform Commercial Code as enacted
and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection,
priority, or remedies and for purposes of definitions relating to such provisions.

 

“Collateral”
is any and all properties, rights and assets of Borrower described on Exhibit A.

 

“Collateral
Account” is any Deposit Account, Securities Account, or Commodity Account.

 

“Commodity
Account” is any “commodity account” as defined in the Code with such additions to such term as may hereafter
be made.

 

“Compliance
Certificate” is that certain certificate in the form attached hereto as Exhibit D.

 

“Contingent
Obligation” is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness,
lease, dividend, letter of credit or other obligation of another such as an obligation, in each case, directly or indirectly guaranteed,
endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable;
(b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate,
currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect
a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation”
does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or determined
amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated
liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any
guarantee or other support arrangement.

 

    	 	31	 

     

    

 

“Control Agreement”
is any control agreement entered into among the depository institution at which Borrower maintains a Deposit Account or the securities
intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Bank
pursuant to which Bank obtains control (within the meaning of the Code) over such Deposit Account, Securities Account, or Commodity
Account, in each case which Control Agreement shall (a) provide the applicable Borrower the right to have access to the relevant
account prior to the giving of a notice of exclusive control or other similar direction by the Bank and (b) shall otherwise be
in form and substance reasonably acceptable to the Bank.

 

“Conversion
Date” is defined in Section 2.1.1(b)(ii).

 

“Copyrights”
are any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship
and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.

 

“Credit Extension”
is the Growth Capital Advance or any other extension of credit by Bank for Borrower’s benefit under this Agreement.

 

“Default Rate”
is defined in Section 2.2(b).

 

“Deposit Account”
is any “deposit account” as defined in the Code with such additions to such term as may hereafter be made.

 

“Designated
Deposit Account” is the multicurrency account denominated in Dollars, account number *******427, maintained by Borrower
with Bank.

 

“Dollars,”
“dollars” or use of the sign “$” means only lawful money of the United States and not any
other currency, regardless of whether that currency uses the “$” sign to denote its currency or may be readily converted
into lawful money of the United States.

 

“Dollar Equivalent”
is, at any time, (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated
in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing
rate of exchange in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign
Currency.

 

“Domestic
Subsidiary” means a Subsidiary of Borrower organized under the laws of the United States or any state or territory thereof
or the District of Columbia.

 

“Effective
Date” is defined in the preamble hereof.

 

    	 	32	 

     

    

 

“Equipment”
is all “equipment” as defined in the Code with such additions to such term as may hereafter be made, and includes without
limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.

 

“ERISA”
is the Employee Retirement Income Security Act of 1974, and its regulations.

 

“Event of
Default” is defined in Section 8.

 

“Exchange
Act” is the Securities Exchange Act of 1934, as amended.

 

“FDA”
means the United States Food and Drug Administration.

 

“Final Payment”
is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due in
accordance with Section 2.1.1 above, equal to the Growth Capital Loan Commitment multiplied by the Final Payment Percentage.

 

“Final Payment
Percentage” is six and one-half percent (6.5%).

 

“Financial
Trigger Event” means that Borrower has not, by May 31, 2018, provided to Bank evidence reasonably satisfactory to Bank
that Borrower has received FDA approval for the sale of TLANDO in the United States.

 

“Financial
Trigger Release Event” means Bank’s receipt, after the occurrence of the Financial Trigger Event, of evidence reasonably
satisfactory to Bank that Borrower has received FDA approval for the sale of TLANDO in the United States.

 

“Foreign Currency”
means lawful money of a country other than the United States.

 

“Foreign Subsidiary”
means any Subsidiary of the Borrower which is not a Domestic Subsidiary.

 

“Funding Date”
is any date on which a Credit Extension is made to or for the account of Borrower, which shall be a Business Day.

 

“FX Contract”
is any foreign exchange contract by and between Borrower and Bank under which Borrower commits to purchase from or sell to Bank
a specific amount of Foreign Currency on a specified date.

 

“GAAP”
is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of
the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards
Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession,
that are applicable to the circumstances as of the date of determination.

 

“General Intangibles”
is all “general intangibles” as defined in the Code in effect on the date hereof with such additions to such term as
may hereafter be made, and includes without limitation, all Intellectual Property, claims, income and other tax refunds, security
and other deposits, payment intangibles, contract rights, options to purchase or sell real or personal property, rights in all
litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation
key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.

 

    	 	33	 

     

    

 

“Governmental
Approval” is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration,
filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.

 

“Governmental
Authority” is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
functions of or pertaining to government, any securities exchange and any self-regulatory organization.

 

“Growth Capital
Advance” is defined in Section 2.1.1(a).

 

“Growth Capital
Loan Commitment” is Ten Million Dollars ($10,000,000).

 

“Growth Capital
Maturity Date is December 1, 2021.

 

“Guarantor”
is any Person providing a Guaranty in favor of Bank. For the avoidance of doubt, it is acknowledged that, as of the Effective Date,
there are no Guarantors.

 

“Guaranty”
is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise
supplemented. For the avoidance of doubt, it is acknowledged that, as of the Effective Date, there are no Guaranties.

 

“Indebtedness”
is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations
for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c)
capital lease obligations, and (d) Contingent Obligations.

 

“Indemnified
Person” is defined in Section 12.3.

 

“Insolvency
Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy
or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or
proceedings seeking reorganization, arrangement, or other relief.

 

“Intellectual
Property” means, with respect to any Person, all of such Person’s right, title, and interest in and to the following:

 

(a)          its
Copyrights, Trademarks and Patents;

 

(b)          any
and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, operating
manuals;

 

(c)          any
and all source code;

 

    	 	34	 

     

    

 

 

(d)          any
and all design rights which may be available such Person;

 

(e)          any
and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the
obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above;
and

 

(f)          all
amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.

 

“Interest-Only
Extension Milestone” means Bank’s receipt, on or prior to May 31, 2018, of evidence reasonably satisfactory to
Bank that Borrower has received FDA approval for TLANDO.

 

“Interest-Only
Period” means the period commencing on the Funding Date of the Growth Capital Advance and continuing through (a) if Borrower
has not satisfied the Interest-Only Extension Milestone, December 31, 2018, or (b) if Borrower has satisfied the Interest-Only
Extension Milestone, June 30, 2019.

 

“Inventory”
is all “inventory” as defined in the Code in effect on the date hereof with such additions to such term as may hereafter
be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work
in process and finished products, including without limitation such inventory as is temporarily out of Borrower’s custody
or possession or in transit and including any returned goods and any documents of title representing any of the above.

 

“Investment”
is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance
or capital contribution to any Person.

 

“Key Person”
is each of Borrower’s (a) President and Chief Executive Officer, who is Mahesh V. Patel as of the Effective Date, and
(b) Executive Vice President and Chief Financial Officer, who is Morgan Brown as of the Effective Date.

 

“Letter of
Credit” is a standby or commercial letter of credit issued by Bank upon request of Borrower based upon an application,
guarantee, indemnity, or similar agreement.

 

“Lien”
is a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind, whether voluntarily
incurred or arising by operation of law or otherwise against any property.

 

“Loan Documents”
are, collectively, this Agreement and any schedules, exhibits, certificates, notices, and any other documents related to this Agreement,
any Bank Services Agreement, all agreements, instruments and documents relating to any Pledged Collateral, any subordination agreement,
any note, or notes or guaranties executed by Borrower or any Guarantor, and any other present or future agreement by Borrower and/or
any Guarantor with or for the benefit of Bank in connection with this Agreement or Bank Services, all as amended, restated, or
otherwise modified.

 

    	 	35	 

     

    

 

“Material
Adverse Change” is (a) a material impairment in the perfection or priority of Bank’s Lien in the Collateral or
in the value of such Collateral (including, without limitation, any Pledged Collateral); (b) a material adverse change in the business,
operations, or condition (financial or otherwise) of Borrower; or (c) a material impairment of the prospect of repayment of any
portion of the Obligations.

 

“Minimum Cash
Collateral Value” means Five Million Dollars ($5,000,000).

 

“Monthly Financial
Statements” is defined in Section 6.2(a).

 

“Obligations”
are Borrower’s obligation to pay when due any debts, principal, interest, fees, Bank Expenses, and other amounts Borrower
owes Bank now or later, whether under this Agreement, the other Loan Documents, or otherwise, including, without limitation, any
interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned to Bank, and the
performance of Borrower’s duties under the Loan Documents.

 

“Operating
Documents” are, for any Person, such Person’s formation documents, as certified by the Secretary of State (or equivalent
agency) of such Person’s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective
Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company,
its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement
(or similar agreement), each of the foregoing with all current amendments or modifications thereto.

 

“Patents”
means all patents, patent applications and like protections including without limitation improvements, divisions, continuations,
renewals, reissues, extensions and continuations-in-part of the same.

 

“Payment/Advance
Form” is that certain form attached hereto as Exhibit B.

 

“Perfection
Certificate” is defined in Section 5.1.

 

“Permitted
Indebtedness” is:

 

(a)          Borrower’s
Indebtedness to Bank under this Agreement and the other Loan Documents;

 

(b)          Indebtedness
existing on the Effective Date and shown on the Perfection Certificate;

 

(c)          Subordinated
Debt;

 

(d)          unsecured
Indebtedness to trade creditors incurred in the ordinary course
of business;

 

(e)          Indebtedness
incurred as a result of endorsing negotiable instruments received in the ordinary course of business;

 

    	 	36	 

     

    

 

(f)          Indebtedness
secured by Liens permitted under clauses (a) and (c) of the definition of “Permitted Liens” hereunder;

 

(g)          Indebtedness
among Borrowers and any secured Guarantors;

 

(h)          Subject
to the restriction that Indebtedness described in this clause (h) and the Investments described in clause (g) of Permitted Investments
shall not in the aggregate exceed One Hundred Thousand Dollars ($100,000), Indebtedness of a Borrower to any Subsidiary that is
not a Borrower or secured Guarantor hereunder and Indebtedness of any Subsidiary that is not a Borrower or secured Guarantor hereunder
to Borrowers;

 

(i)          extensions,
refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (h) above, provided
that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower
or its Subsidiary, as the case may be;

 

(j)          Indebtedness
in connection with commercial credit cards outside of Bank, in an aggregate amount not exceeding One Hundred Thousand Dollars ($100,000)
at any time outstanding; and

 

(k)          Other
unsecured Indebtedness not otherwise permitted by Section 7.4, in an aggregate amount not exceeding Fifteen Thousand Dollars ($15,000)
at any time outstanding.

 

“Permitted
Investments” are:

 

(a)          Investments
shown on the Perfection Certificate and existing on the Effective Date;

 

(b)          (i)
Investments consisting of Cash Equivalents, (ii) Investments in Collateral Accounts maintained at Bank or Bank’s Affiliates
that are managed by Bank or Bank’s Affiliates, and (iii) any Investments permitted by Borrower’s investment policy,
as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing
by Bank;

 

(c)          Investments
consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course
of Borrower;

 

(d)          Investments
consisting of deposit accounts in which Bank has a perfected security interest (except for (i) the payroll, payroll tax and other
employee wage and benefit payments accounts to or for the benefit of Borrower’s employees, if any, permitted pursuant to
Section 6.6(b) and (ii) so long as a Control Agreement has not been obtained on the Chase Accounts as permitted in Section 3.3(b),
the Chase Accounts);

 

(e)          Investments
accepted in connection with Transfers permitted by Section 7.1;

 

    	 	37	 

     

    

 

(f)          Investments
consisting of the creation of a Subsidiary for the purpose of consummating a merger transaction permitted by Section 7.3 of this
Agreement, which is otherwise a Permitted Investment;

 

(g)          Subject
to the restriction that Investments described in this clause (g) and the Indebtedness described in clause (h) of Permitted Indebtedness
shall not in the aggregate exceed One Hundred Thousand Dollars ($100,000), (i) Investments of Subsidiaries that are secured Guarantors
in or to other Subsidiaries that are secured Guarantors or Borrower and Investments by Borrower in Subsidiaries that are secured
Guarantors, and (ii) Investments (A) by Borrowers in their Subsidiaries that are not Borrowers or secured Guarantors hereunder,
and (B) by Subsidiaries that are not Borrowers or secured Guarantors hereunder in other Subsidiaries that are not Borrowers or
secured Guarantors hereunder.

 

(h)          Investments
consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of
business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries
pursuant to employee stock purchase plans or agreements approved by Borrower’s Board of Directors;

 

(i)          Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;

 

(j)          Investments
consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates,
in the ordinary course of business; provided that this paragraph (j) shall not apply to Investments of Borrower in any Subsidiary;
and

 

(k)          Other
Investments in an amount not exceeding One Hundred Thousand Dollars ($100,000) in the aggregate outstanding at any time.

 

“Permitted
Liens” are:

 

(a)          Liens
existing on the Effective Date and shown on the Perfection Certificate or arising under this Agreement and the other Loan Documents;

 

(b)          Liens
for taxes, fees, assessments or other government charges or levies, either not due and payable or being contested in good faith
and for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed
or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder;

 

(c)          purchase
money Liens (i) on Equipment acquired or held by Borrower incurred for financing the acquisition of the Equipment securing no more
than Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate amount outstanding, or (ii) existing on Equipment when acquired,
if the Lien is confined to the property and improvements and the proceeds of the Equipment;

 

    	 	38	 

     

    

 

(d)          Liens
of carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business
so long as such Liens attach only to Inventory and related property, securing liabilities in the aggregate amount not to exceed
One Hundred Thousand Dollars ($100,000) and which are not delinquent or remain payable without penalty or which are being contested
in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property
subject thereto;

 

(e)          Liens
to secure payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations
incurred in the ordinary course of business (other than Liens imposed by ERISA);

 

(f)          Liens
incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (c); provided that
any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount
of the indebtedness may not increase;

 

(g)          leases
or subleases of real property granted in the ordinary course of Borrower’s business (or, if referring to another Person,
in the ordinary course of such Person’s business), and leases, subleases, non-exclusive licenses or sublicenses of personal
property (other than Intellectual Property) granted in the ordinary course of Borrower’s business (or, if referring to another
Person, in the ordinary course of such Person’s business);

 

(h)          non-exclusive
licenses of Intellectual Property granted to third parties in the ordinary course of business and leases, subleases, non-exclusive
licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of a Borrower’s
business (or, if referring to another Person, in the ordinary course of such Person’s business);

 

(i)          Liens
arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default under Sections
8.4 and 8.7;

 

(j)          Liens
in favor of other financial institutions arising in connection with Borrower’s deposit and/or securities accounts held at
such institutions so long as Borrower is in compliance with Section 6.6 hereof;

 

(k)          easements,zoningrestrictions,rights-of-way,minordefectsor
irregularities in title and similar encumbrances on real property imposed by law or arising in the ordinary course of business
which (i) do not secure obligations for the payment of money, (ii) are not material in amount and (iii) do not materially detract
from or impair the value of the affected property or interfere materially with the ordinary conduct of business of Borrower; and

 

(l)          Liens
with respect to security deposits given by Borrower to secure real estate leases not exceeding One Hundred Thousand Dollars ($100,000)
in the aggregate outstanding at any time.

 

“Person”
is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.

 

    	 	39	 

     

    

 

“Pledged Collateral”
means a cash collateral account maintained with Bank by Borrower, which account shall be restricted such that neither Borrower
nor any other Person (other than Bank) shall be entitled to withdraw or transfer any funds from such accounts, place any Liens
on such accounts other than in favor of Bank, or otherwise dispose of the funds in such accounts and which accounts shall be subject
to a first priority perfected security interest in favor of Bank.

 

“Prepayment
Fee” shall be an amount equal to (i) two percent (2%) of the
outstanding principal balance of the Growth Capital Advance if the principal balance of the Growth Capital Advance is outstanding
one (1) year or less, or (ii) one percent (1%) of the outstanding principal balance of the Growth Capital Advance if the principal
balance of the Growth Capital Advance is outstanding more than one (1) year and less than two (2) years. There shall be no Prepayment
Fee if the principal balance of the Growth Capital Advance is outstanding two (2) years or more.

 

“Prime Rate”
is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any
successor publication thereto as the “prime rate” then in effect; provided that, in the event such rate of interest
is less than zero, such rate shall be deemed to be zero for purposes of this Agreement; and provided further that if such rate
of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for
any reason as determined by Bank, the “Prime Rate” shall mean the rate of interest per annum announced by Bank as its
prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be
the lowest rate of interest charged by Bank in connection with extensions of credit to debtors).

 

“Registered
Organization” is any “registered organization” as defined in the Code with such additions to such term as
may hereafter be made.

 

“Repayment
Period” is the period of time commencing on the Conversion Date and continuing through the Growth Capital Maturity Date.

 

“Requirement
of Law” is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common),
treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable
to or binding upon such Person or any of its property or to which such Person or any of its property is subject.

 

“Responsible
Officer” is any of the Chief Executive Officer, President, Chief Financial Officer or Controller of Borrower.

 

“Restricted
License” is any material license or other agreement with respect to which Borrower is the licensee (a) that prohibits
or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or
any other property, or (b) for which a default under or termination of could interfere with Bank’s right to sell any
Collateral. Notwithstanding anything to the contrary, “Restricted License” shall not include any license of over-the-counter
software that is commercially available to the public.

 

“SEC”
shall mean the Securities and Exchange Commission, any successor thereto, and any analogous Governmental Authority.

 

    	 	40	 

     

    

 

“Securities
Account” is any “securities account” as defined in the Code with such additions to such term as may hereafter
be made.

 

“Subordinated
Debt” is indebtedness incurred by Borrower subordinated to all of Borrower’s now or hereafter indebtedness to Bank
(pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Bank entered into
between Bank and the other creditor), on terms acceptable to Bank.

 

“Subsidiary”
is, as to any Person, a corporation, partnership, limited liability company or other entity of which shares of stock or other ownership
interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of
the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, partnership
or other entity are at the time owned, or the management of which is otherwise controlled, directly or indirectly through one or
more intermediaries, or both, by such Person. Unless the context otherwise requires, each reference to a Subsidiary herein shall
be a reference to a Subsidiary of Borrower or Guarantor.

 

“Trademarks”
means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and
like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.

 

“Transfer”
is defined in Section 7.1.

 

[Signature page follows.]

 

    	 	41	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be executed as of the Effective Date.

 

BORROWER:

 

LIPOCINE INC.

 

	By:	 	 
	 	Name: 	 	 
	 	Title:	 	 
	 	 	 
	LIPOCINE OPERATING INC.	 
	 	 	 
	By:	 	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 
	BANK:	 
	 	 	 
	SILICON VALLEY BANK	 
	 	 	 
	By:	 	 
	 	Name:	 	 
	 	Title:	 	 

 

[Signature Page to Loan and Security Agreement]

 

     

     

    

 

EXHIBIT
A

 

The Collateral consists
of all of Borrower’s right, title and interest in and to the following personal property:

 

All goods, Accounts
(including health-care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements,
franchise agreements, General Intangibles (except as provided below), commercial tort claims, documents, instruments (including
any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, fixtures, letters of credit rights
(whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations,
and financial assets, in each of the foregoing cases, whether now owned or hereafter acquired, wherever located; and

 

All Borrower’s
Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions,
attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or
all of the foregoing.

 

Notwithstanding anything
to the contrary herein, the Collateral does not include any of the following, whether now owned or hereafter acquired: (a) more
than sixty-five percent (65%) of the presently existing and hereafter arising issued and outstanding shares of capital stock owned
by Borrower of any Foreign Subsidiary which shares entitle the holder thereof to vote for directors or any other matter; (b) any
intent-to-use trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording
of a statement of use with the United States Patent and Trademark Office or otherwise; (c) rights held under a license that are
not assignable by their terms without the consent of the licensor thereof (but only to the extent such restriction on assignment
is enforceable under applicable law); (d) any interest of Borrower as a lessee under an Equipment lease if Borrower is prohibited
by the terms of such lease from granting a security interest in such lease or under which such an assignment or Lien would cause
a default to occur under such lease; provided, however, that upon termination of such prohibition, such interest shall immediately
become Collateral without any action by Borrower or Bank; or (e) Intellectual Property; provided, however, the Collateral shall
include all Accounts and all proceeds of Intellectual Property. If a judicial authority (including a U.S. Bankruptcy Court) would
hold that a security interest in the underlying Intellectual Property is necessary to have a security interest in such Accounts
and such property that are proceeds of Intellectual Property, then the Collateral shall automatically, and effective as of the
Effective Date, include the Intellectual Property to the extent necessary to permit perfection of Bank’s security interest
in such Accounts and such other property of Borrower that are proceeds of the Intellectual Property.

 

Pursuant to the terms
of Section 7.5 and except for Permitted Liens, Borrower has agreed not to encumber any of its Intellectual Property without Bank’s
prior written consent.

 

    	 	A-1	 

     

    

 

EXHIBIT B

 

Loan Payment/Advance Request Form

 

Deadline
for same day processing is Noon Pacific Time.

 

	Fax To:  (858) 622-1424	Date: _____________________

 

LOAN PAYMENT:

LIPOCINE INC. and LIPOCINE OPERATING
INC.

 

	From Account #________________________________	To Account #____________________________________
	(Deposit Account #)	(Loan Account #)

	Principal $____________________________________	and/or Interest $__________________________________
	Authorized Signature:_____________________________	Phone Number:___________________________________
	Print Name/Title:__________________________________	 

 

Loan Advance:

 

Complete Outgoing Wire Request section below if all or
a portion of the funds from this loan advance are for an outgoing wire.

 

	From Account #_________________________________	To Account #____________________________________
	(Loan Account #)	(Deposit Account #)

Amount of Advance $___________________________

 

All Borrower’s representations and warranties in the Loan
and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance; provided,
however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified
or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring
to a specific date shall be true, accurate and complete in all material respects as of such date:

 

	Authorized Signature:  ___________________________	Phone Number: __________________________
	Print Name/Title:  ________________________________	 

 

Outgoing Wire Request:

Complete only if all or a portion of funds from the loan
advance above is to be wired.

Deadline for same day processing is noon, P.S.T.

 

	Beneficiary Name: _____________________________	 	Amount of Wire: $________________________________
	Beneficiary Bank: ______________________________	 	Account Number:_________________________________

City and State:

 

	Beneficiary Bank Transit (ABA) #: ___________	 	Beneficiary Bank Code (Swift, Sort, Chip, etc.):
	 	 	(For International Wire Only)

 

	Intermediary Bank: _______________________	 	Transit (ABA) #: _____________________________________

For Further Credit to:______________________________________________________________________________

 

Special Instruction:________________________________________________________________________________

 

By signing below, I (we) acknowledge and agree that my (our)
funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s)
covering funds transfer service(s), which agreements(s) were previously received and executed by me (us).

 

	Authorized Signature: ___________________________	2nd Signature (if required): ___________________________
	Print Name/Title: _______________________________	Print Name/Title: __________________________________
	Telephone #: _________________________________	Telephone #:  ____________________________________

 

    	 	B-1	 

     

    

 

EXHIBIT C

 

BORROWING RESOLUTIONS

 

[see attached]

 

    	 	C-1	 

     

    

 

EXHIBIT D

 

COMPLIANCE CERTIFICATE

 

	TO:	SILICON VALLEY BANK	 	Date: ________________________
	FROM:	LIPOCINE INC. and LIPOCINE OPERATING INC.	 	 

 

The undersigned, solely
in his or her capacity as an authorized officer of LIPOCINE INC., on behalf of LIPOCINE INC. and LIPOCINE OPERATING INC. (individually
and collectively, jointly and severally, “Borrower”), certifies that under the terms and conditions of the Loan and
Security Agreement between Borrower and Bank (the “Agreement”), (1) Borrower is in complete compliance for the period
ending _______________ with all required covenants except as noted below, (2) there are no Events of Default, (3) all representations
and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however,
that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified
by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific
date shall be true, accurate and complete in all material respects as of such date, (4) Borrower, and each of its Subsidiaries,
has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes,
assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 5.8 of
the Agreement, and (5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid
employee payroll or benefits of which Borrower has not previously provided written notification to Bank, except as noted below.
Attached are the required documents supporting the certification. The undersigned, solely in his or her capacity as an authorized
officer of Borrower, certifies that these are prepared in accordance with GAAP consistently applied from one period to the next
except as explained in an accompanying letter or footnotes. The undersigned, solely in his or her capacity as an authorized officer
of Borrower, acknowledges that no borrowings may be requested at any time or date of determination that Borrower is not in compliance
with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized
terms used but not otherwise defined herein shall have the meanings given them in the Agreement.

 

Please indicate compliance status by circling Yes/No under
“Complies” column.

 

	Reporting Covenant	 	Required	 	Complies
	 	 	 	 	 
	Quarterly financial statements with Compliance Certificate	 	Quarterly within 45 days (Q1 – Q3)	 	Yes  No
	Annual financial statements (CPA Audited) + CC	 	FYE within 90 days	 	 
	Annual Board Approved Financial Projections	 	FYE within 30 days (and as updated)	 	Yes  No

 

The following are the exceptions with respect to the certification
above: (If no exceptions exist, state “No exceptions to note.”)

 

 

 

	LIPOCINE INC., on behalf of itself and all Borrowers	 	BANK USE ONLY
	 	 	 	 
	By:	 	 	Received by:	 
	Name:	 	 	 	authorized signer
	Title:	 	 	Date:	 
	 	 	 	 	 
	 	 	 	Verified:	 
	 	 	 	 	authorized signer
	 	 	 	Date:	 
	 	 	 	 	 
	 	 	 	Compliance Status:  Yes  No

 

    	 	D-1Exhibit 10.14

 Exhibit 10.14
  
 Confidential Treatment Requested by ITUS Corporation,
 IRS Employer Identification No. 11-2622630
  
 ***CONFIDENTIAL TREATMENT REQUESTED*** 
  
 Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]”
 LICENSE AGREEMENT
 This LICENSE AGREEMENT (the “Agreement”) Is made as of the 13th day of November, 2017 (the “Effective Date”), by and between THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, a nonprofit corporation organized and existing under the laws of the Commonwealth of Pennsylvania located at 3601 Spruce Street, Philadelphia, PA 19104 (“Wistar”), and Certainty Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware with principal offices located at 3150 Almaden Expressway, Suite 250, San Jose, California 95118 (“Company”). 
 BACKGROUND
 WHEREAS, Wistar owns or controls certain intellectual property as specifically described in Schedule I attached hereto and incorporated herein by reference (as further defined hereinafter, the “Licensed Patents”); 
 WHEREAS, Company is a majority owned corporation of ITUS Corporation, a corporation organized and existing under the laws of the State of Delaware with a principal place of business located at 3150 Almaden Expressway, Suite 250, San Jose, California 95118 (“ITUS”); 
 WHEREAS, Wistar and ITUS entered into an exclusive option agreement on May 18, 2017 granting ITUS a period of time in which to (i) evaluate the Licensed Patents, potential products arising therefrom and markets therefor and (ii) elect to negotiate a license with Wistar for the use of the Licensed Patents (the “Option”);
  
 WHEREAS, in accordance with the terms and conditions set forth in the Option, Company wishes to enter into an exclusive license agreement granting to Company certain rights in and to the Licensed Patents;
 WHEREAS, Company is capable of and committed to developing and commercializing products utilizing such rights; 
 WHEREAS, concurrent with the execution of this Agreement, Wistar will be receiving an equity interest in the Company; and
  
1 

 
  
 WHEREAS, Wistar is willing to grant such a license to Company, in consideration of Company’s satisfaction of its obligations hereunder, and for other good and valuable consideration as set forth herein.
 NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and intending to be legally bound hereby, the parties hereto agree as follows:
             Article 1 - DEFINITIONS
 The following terms, as used herein, shall have the following meanings: 
 1.1.            “Affiliate” means, when used with reference to a Person, any Person directly or indirectly controlling, controlled by or under common control with, such Person.  For the purposes of this definition, “control” means the direct or indirect ownership of over fifty percent (50%) of the outstanding voting securities of a Person, or the right to receive over fifty percent (50%) of the profits or earnings of a Person, or the ability to control the decisions of a Person.
 1.2.            “Agreement” has the meaning set forth in the Preamble.  
 1.3.            “Anti-Corruption Laws” shall mean any anti-bribery and anti-corruption laws, rules, regulations applicable to a party under this Agreement (each as amended from time to time) including the Prevention of Corruption Act (cap.241) of Singapore, the U.S. Anti-Kickback Law, U.S. Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention Against the Bribery of Foreign Government Officials in International Business Transactions, together with any applicable implementing legislation, including any applicable local law addressing bribery or corruption.
 1.4.            “Bankruptcy Event” means, with respect to any Person, any of the following:
 (i)                 such Person shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due, or shall take any corporate action to authorize any of the foregoing;
 (ii)               an involuntary case or other proceeding shall be commenced against such Person seeking liquidation, reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of sixty (60) days; or an order for relief shall be entered against such Person under the federal bankruptcy laws as now or hereafter in effect; or
 2 

 
  (iii)             a receiver or trustee shall be appointed with respect to such Person or all or substantially all of the assets of such Person.
 1.5.            “Bar Date” has the meaning set forth in Section 7.1.1.
 1.6.            “Calendar Quarter” means each three (3) month period, or any portion thereof, beginning on January 1, April 1, July 1 and October 1 of each year.
 1.7.            “Clinical Trials” means any administration of Licensed Products to humans for the purpose of demonstrating the safety or efficacy of the Licensed Product. 
 1.8.            “Commercialization Plan” has the meaning set forth in Section 4.2.1.
 1.9.            “Company” has the meaning set forth in the Preamble.
 1.10.        “Company Confidential Information” has the meaning set forth in Section 8.1.1. 
 1.11.        “Company IP” has the meaning set forth in Section 9.6(iii).
 1.12.        “Confidential Information” has the meaning set forth in Section 8.1.1.
 1.13.        “Control” or “Controlled” means, with respect to the Licensed Technical Information, possession of the ability (whether by sole, joint or other ownership interest, license or otherwise, other than pursuant to this Agreement) to, without violating the terms of any agreement with a third party, grant a license or sublicense or provide access or other rights in, to or under such Licensed Technical Information. 
 1.14.         “Dilution Protection Cap” has the meaning set forth in Section 3.1.2(ii).
 1.15.        “Documentation and Approvals” has the meaning set forth in Section 9.6(i).
 1.16.        “EAR” or “Export Administration Regulations” has the meaning set forth in Section 4.5.2.
 1.17.        “Effective Date” has the meaning set forth in the Preamble.
 1.18.         “Equity Securities” has the meaning set forth in Section 1.1.3.1.2(v) 
 1.19.        “First Commercial Sale” means the first sale, transfer, disposition, performance, or practice for value of a Licensed Product.
 3 

 
   1.20.        “Fully Diluted Capitalization” has the meaning set forth in Section 3.1.2(i).
 1.21.        “Funding Agency Interest” has the meaning set forth in Section 2.2.2.
 1.22.        “IND Filing” means the preparation and filing of a “Notice of Claimed Investigational Exemption for a New Drug” with the U.S. Food and Drug Administration (FDA), or any comparable filing in a foreign jurisdiction.
 1.23.        “Indemnified Party” and “Indemnified Parties” have the meaning set forth in Section 6.3.
 1.24.        “ITAR” or “International Traffic in Arms Regulations” has the meaning set forth in Section 4.5.2.
 1.25.        “Liability” and “Liabilities” have the meaning set forth in Section 6.2.
 1.26.        “Licensed Field” means chimeric endocrine receptor targeted therapy for any human therapeutic and diagnostic use. 
 1.27.        “Licensed Patents” means (i) the patent applications set forth on Schedule I hereto, (ii) all patents issuing from such applications, (iii) all continuations, continuations-in-part, additions, divisions, renewals, extensions, reexaminations and reissues of any of the foregoing, that claim the benefit of priority to the applications or patents referenced in (i) or (ii) hereof, and (iv)any patents in the Territory issuing from any applications filed after the Effective Date from which any of the patents or patent applications identified in (i), (ii), or (iii) claim priority.
 1.28.        “Licensed Products” means: 
 (i)                 any product, the making, using, selling, offering for sale, or importing of which product would (without the license granted under this Agreement) infringe at least one pending Valid Claim (were it to have issued) or issued Valid Claim of the Licensed Patents in any country;
 (ii)               any service, process or method, the performing or providing of which process or method would (without the license granted under this Agreement) infringe at least one pending Valid Claim (were it to have issued) or issued Valid Claim of the Licensed Patents in any country; and
 (iii)             any product or process that is not covered by the foregoing clauses (i) or (ii), but that uses, incorporates or is made, identified, developed, optimized, characterized, selected, derived or determined to have utility, in whole or in part, by the use or modification of (a) any Licensed Patent or any technology or invention covered thereby, (b) any Licensed Technical Information, or (c) any Licensed Product covered by the foregoing clauses (i) or (ii) or (iii). 
 4 

 
  1.29.        “Licensed Technical Information” means technical information, know-how, protocols, data, techniques and other information that are not generally known laboratory techniques that pertain to the Licensed Patents and are necessary in the manufacture, sale, or use of the Licensed Products (i) made or developed by Dr. Jose Conejo-Garcia or laboratory personnel working directly under his supervision at  Wistar, (ii) owned and Controlled by Wistar, and (iii) in Wistar’s possession as of the Effective Date.  Licensed Technical Information shall exclude any of the foregoing information that is included in the written description of any of the Licensed Patents or any other patents or patent applications and shall also exclude (i) information that the Company can demonstrate by documentation: (a) was already known without restriction on use or disclosure prior to receipt of such information directly or indirectly from or on behalf of Wistar; (b) was or is independently developed without reference to or use of any of the Licensed Technical Information; (c) was or becomes generally known by the public other than by breach of this Agreement by Company, or other wrongful act of, Company; or (d) was received by Company from a third party who was not, at the time of receipt, under any obligation to Wistar or any other person to maintain the confidentiality of such information.
 1.30.        “Minimum Annual Royalties” has the meaning set forth in Section 3.4.
 1.31.        “Net Sales” means for each Licensed Product for any period, the gross amount actually collected by Company, its Affiliates and Sublicensees from third parties or end users for such Licensed Product including consideration in addition to cash less the following deductions: (i) customary trade, quantity and cash discounts actually allowed for Licensed Products, (ii) taxes levied on sale or transportation of Licensed Products and paid by or on behalf of Company, its Affiliates, or Sublicensees, and (iii) freight allowances, insurance and custom duties for Licensed Products.  In the case of a sale or other transfer of a Licensed Product for which Company or a Sublicensee does not bill, Net Sales shall mean the amount received by Company and Sublicensees for the sale of such Licensed Product.  If a Licensed Product is sold or otherwise transferred for consideration other than solely cash (whether or not at a discount), or if Licensed Product is billed or otherwise sold at a discounted price that is substantially lower than the customary prices charged by Company or Sublicensee, Net Sales shall mean what is actually received by the Company or Sublicensee in cash or other non-cash consideration, such non-cash consideration shall be calculated based on the fair market value of the consideration received.
 5 

 
  1.32.        “Non-Royalty Sublicensing Income” means the fair market value of any and all consideration received by Company and its Affiliates from Sublicensees (or which Company is entitled to receive, whether or not offset against amounts payable to Sublicensee under the Sublicense) under or otherwise in connection with its Sublicenses, including license issue fees, lump sum payments and other licensing fees, option fees, milestone payments, minimum annual royalties, distribution fees, joint marketing fees, equity or other payments of any kind whatsoever, irrespective of whether such consideration is received in the form of cash, barter, credit, stock, warrants, release from debt, goods or services, licenses back, a premium on the sale of equity (i.e., payments for equity that exceed the pre-Sublicense fair market value of the equity), equity exchanges, or any other form whatsoever.  Notwithstanding the foregoing, Non-Royalty Sublicensing Income specifically excludes:  (i) royalties on Net Sales pursuant to Section 3.2; and (ii) payments made by Sublicensee as consideration for the issuance of equity or debt securities of Company at the pre-Sublicense fair market value, provided that if a Sublicensee pays more than such fair market value for equity or debt securities then the portion in excess of fair market value shall be considered Non-Royalty Sublicensing Income and (iii) payments to Company for the purposes of funding the costs of future bona fide documented research of a Licensed Product to be conducted by the Company and (iv) payments received directly for Patenting Costs. For the purposes of Non-Royalty Sublicensing Income, the term “fair market value” means the cash consideration which Company, its Affiliates or any Sublicensees would realize from an unaffiliated, unrelated buyer in an arm’s length sale of an identical item sold in the same quantity and at the same time and place of the transaction. Non-Royalty Sublicensing Income that is a percentage of milestone payments received by Company from a Sublicensee shall be available for credit against miles tone payments payable to Wistar by Company under Section 3.7.
 1.33.        “OFAC” or “Office of Foreign Assets Control” has the meaning set forth in Section 4.5.2.
 1.34.        “Option” has the meaning set forth in the Background. 
 1.35.        “Past Patenting Costs” has the meaning set forth in Section 7.1.1.
 1.36.        “Patent Challenge” means any direct or indirect dispute, challenge, or assistance in the challenge of the validity, patentability, scope, construction, enforceability, non-infringe­ment or Wistar’s ownership of any issued patent comprising the Licensed Patents or any claims thereof, or opposition or assistance in the opposition of the grant of any letters patent comprising the Licensed Patents, in any legal or, administrative proceedings, including in a court of law, before the United States Patent and Trademark Office or other agency or tribunal in any jurisdiction, or in arbitration.
 1.37.        “Patent Term Extension” has the meaning set forth in Section 0.
 1.38.        “Patenting Costs” means any past or ongoing costs incurred or to be incurred, including government fees and attorneys’ fees, in the course of Prosecuting the Licensed Patents.
 6

 
 
 1.39.        “Performance Milestone(s)” has the meaning set forth in Section 4.2.
 1.40.        “Performance Milestone Dates” has the meaning set forth in Section 4.2. 
 1.41.        “Performance Milestone Extension Fee” has the meaning set forth in Section 4.3.
 1.42.        “Person” or “Persons” means any corporation, partnership, joint venture or any other entity or any natural person.
 1.43.        “Proposed Product” means an actual or potential Licensed Product that is for an application, product, sub-field or indication in the Licensed Field, but for which a Licensed Product is not being actively developed or commercialized by Company, its Affiliates or Sublicensees. 
 1.44.        “Proposed Product Election Notice” has the meaning set forth in Section 2.5.2.
 1.45.        “Proposed Product Notice” has the meaning set forth in Section 2.5.1.
 1.46.         “Proposed Product Sublicense” has the meaning set forth in Section 2.5.4.
 1.47.        “Proposing Third Party” has the meaning set forth in Section 2.5.1. 
 1.48.        “Prosecution” or “Prosecuting” means preparation, filing, prosecution, issuance and maintenance of the Licensed Patents, including continuations, continuations-in-part, divisionals, extensions, re-examinations, reissues, supplemental examination, appeals, interferences, derivation proceedings, oppositions, all other proceedings before the United States Patent and Trademark Office (including the Patent Trial and Appeal Board) and foreign patent offices, and any judicial or other appeals of the foregoing. 
 1.49.        “Qualified Sublicensee” means a Sublicensee with (a) specific experience in the Licensed Field and (b) sufficient human and financial resources to develop and commercialize Licensed Products in the Licensed Field.
 1.50.        “Regulatory Approval” means, with respect to any jurisdiction, any and all approvals (including appropriate pricing and reimbursement approvals), product and/or establishment licenses, registrations or authorizations of any appropriate regulatory agency, department, bureau or other governmental entity, necessary for marketing a Licensed Product in such jurisdiction, as applicable. 
 1.51.        “Royalty Term” has the meaning set forth in Section 3.3.
 1.52.        “Shares” has the meaning set forth in Section 3.1.2(i).
 7

 
 
 1.53.        “Sublicense” means an agreement in which Company (i) grants or otherwise transfers any of the rights licensed to Company hereunder or other rights that are relevant to designing, developing, testing, making, using, selling, importation, exporting or distribution of Licensed Products in the Territory, (ii) agrees not to assert such rights or to sue, prevent or seek a legal remedy for the practice of same, or (iii) is under an obligation to grant, assign or transfer any such rights or non-assertion, or to forebear from granting or transferring such rights to any other entity, including by means of an option.  Agreements expressly considered Sublicenses include licenses, option agreements, “lock up” agreements, right of first refusal agreements, non-assertion agreements, covenants not to sue, distribution agreements research and development agreements or similar agreements.  For the avoidance of doubt, any Proposed Product Sublicense shall be a Sublicense as such term is used hereunder. 
 1.54.        “Sublicensee” means any non-Affiliate third party to which Company has granted a Sublicense.
 1.55.        “Term” means the term of this Agreement, which shall commence on the Effective Date and shall remain in effect until the expiration of the Royalty Term in all countries in the Territory with respect to all Licensed Products, unless earlier terminated in accordance with the provisions of this Agreement.
 1.56.        “Territory” means the world.
 1.57.         “Third Party Payment(s)” has the meaning set forth in Section 3.2.2.
 1.58.         “Third Party Proposed Product” has the meaning set forth in Section 2.5.1. 
 1.59.        “Valid Claim” means a claim of (i) a patent application included in the Licensed Patents that has been neither abandoned nor pending for more than ten (10) years or (ii) an issued Licensed Patent that has not been withdrawn, canceled or disclaimed or held invalid by a court or governmental authority of competent jurisdiction in an unappealed or unappealable decision no longer subject to discretionary review (for example, by way of writ of certiorari) or other review.
 1.60.        “Wistar” has the meaning set forth in the Preamble.
 1.61.        “Wistar Confidential Information” has the meaning set forth in Section 8.1.1.
 1.62.        “Wistar Proposed Product” has the meaning set forth in Section 2.5.1.
 1.63.        “Withholding Taxes” has the meaning set forth in Section 3.9.3. 
 8

 
 
 Article 2 - GRANT OF LICENSE
 2.1                       Grant of License.
 2.1.1.      Subject to the terms and conditions contained in this Agreement, Wistar hereby grants to Company an exclusive, royalty-bearing, transferable (as permitted under Section 10.1), sublicensable (as permitted under Section 2.4) license under the Licensed Patents and the Licensed Technical Information (such rights are unencumbered and available for licensing), solely to develop, make, have made, use, sell, offer for sale, export, and import the Licensed Products in the Licensed Field in the Territory during the Term.  
 2.2                       Retained Rights.
 2.2.1.      Reservation by Wistar.  Notwithstanding anything to the contrary in this Agreement, Wistar reserves the right to (i) make, use,  practice and further develop the Licensed Patents and Licensed Technical Information for non-commercial, educational and research purposes; (ii) grant to any academic, government, research or non-profit institution or organization the right to make, use and practice the Licensed Patents and Licensed Technical Information for non-commercial research and educational purposes; (iii) grant licenses under the Licensed Patents and Licensed Technical Information to any party for any field, product, service or territory other than the Licensed Products in the Licensed Field in the Territory for so long as Company has an exclusive license to the Licensed Patents and Licensed Technical Information for Licensed Products in the Licensed Field in the Territory.  Wistar’s reserved rights in research conducted pursuant to another bona fide collaborative research agreement (CRA) or similar contract between Wistar and Company shall be governed by the terms and conditions of such CRA or similar contract, as the case may be.
 2.2.2.      Funding Agency Interest.  Notwithstanding anything to the contrary in this Agreement, any and all licenses and other rights granted hereunder are limited by and subject to the rights and requirements of (a) the U.S. Government under any law or agreement, including rights and requirements which may attach as a result of U.S. Government sponsorship of research in connection with which an invention covered by the Licensed Patents was conceived or first actually reduced to practice, as set forth in 35 U.S.C. §§200-212, and 37 C.F.R. Part 401, or any successor statutes or regulations, and in relevant U.S. Government research grants or contracts with Wistar, as such rights and requirements may be amended or modified by law, rule or regulation, and (b) any local, state or philanthropic funding agencies or entities in inventions funded in whole or in part under any contract, grant or similar agreement with such agency or entity (collectively, the “Funding Agency Interest”). Such rights and requirements include (i) the grant of a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States Government any of the Licensed Patents throughout the world (as set forth in 35 U.S.C. §202(c)(4)), and (ii) the requirement that Licensed Products used or sold in the U.S. shall be manufactured substantially in the U.S. (as set forth in 35 U.S.C. §204).  
 9

 
 
 2.3                       No Rights or Licenses by Implication.  No rights or licenses with respect to the Licensed Patents, Licensed Technical Information, or otherwise are granted or deemed granted hereunder or in connection herewith, other than those rights or licenses expressly granted in this Agreement.
 2.4                       Right to Sublicense.  Company shall have the right to sublicense to any third party the rights conferred upon Company under this Agreement, subject to the following conditions:
 2.4.1.      Company shall provide *** written notice to Wistar prior to the effective date of any Sublicense. 
 2.4.2.      *** 
 2.4.3.      2.4.3Any Sublicense shall be in writing, shall be consistent with all of the terms and conditions of this Agreement, and shall incorporate terms and conditions sufficient to enable Company to comply with this Agreement. Without limiting the foregoing, each Sublicense shall ***. Subject to Sections 2.4.2 and 2.4.3, Sublicensees shall be permitted to sublicense further any of their rights under any Sublicense.  Each Sublicense shall contain an agreement and acknowledgment by the Sublicensee that such Sublicense and the Sublicensee are subject to the terms and conditions of the license granted to Company under this Agreement.  
  
 2.4.4.      Notwithstanding any Sublicense, Company shall remain primarily liable to Wistar for all of Company’s duties and obligations contained in this Agreement, and any act or omission of a Sublicensee which would be a breach of this Agreement if performed by Company shall be deemed to be a breach by Company of this Agreement. 
 2.4.5.      ***
 2.4.6.      If Company becomes subject to a Bankruptcy Event, all payments then or thereafter due and owing to Company from its Sublicensees shall thereupon, and without any notice from Wistar to any such Sublicensee, become payable directly to Wistar for the account of Company; provided, however, that Wistar shall remit to Company any amount by which such payments exceed the amounts owed by Company to Wistar. 
 2.4.7.      Wistar shall have the right to require any Sublicensee, as a condition for effectiveness of a Sublicense, to enter into an agreement with Wistar providing for the redirection of payments to Wistar as provided in Section 2.4.6 in the event that Company becomes subject to a Bankruptcy Event and/or acknowledging that the Sublicense is terminated in the event of any termination of this Agreement, expect as otherwise provided in Section 9.4.
 2.4.8.      Company shall furnish Wistar with a fully executed copy of any Sublicense agreement within thirty (30) days after execution without redaction.  
 10

 
 
 2.4.9.      Any sublicense that is not in compliance with any of the provisions of this Section 2.4 shall be void.
 2.5                       Wistar or Third Party Proposed Products.
 2.5.1.      ***
 2.5.2.      ***
 2.5.3.      *** 
 2.5.4.      ***
  Article 3 - PAYMENTS
 3.1                       Compensation.  
 3.1.1.      License Fee.  In partial consideration of the license granted hereunder, Company shall pay to Wistar a nonrefundable, non-creditable license fee of *** U.S. dollars ($*** USD) (the “License Fee”) due on the following schedule: 
 (i)                 *** U.S. dollars ($*** USD) shall be paid upon execution of this Agreement; 
 (ii)               *** U.S. dollars ($*** USD) shall be paid upon the one (1) year anniversary of the Effective Date of this Agreement; and
 (iii)             *** U.S. dollars ($*** USD) upon the earliest to occur of (a) issuance of the first Valid Claim of a Licensed Patent, or (b) the third (3rd) anniversary of the Effective Date of this Agreement. 
 3.1.2.      Issuance of Shares.  
 (i)                 In partial consideration of the licenses granted hereunder and upon the execution hereof, Company shall issue to Wistar fifty (50) shares of its common stock (the “Shares”), par value $0.01 per share, as will cause Wistar to own five percent (5%) of the Company on a fully diluted basis as of the date hereof that includes (a) any outstanding shares, (b) all outstanding vested and unvested options to acquire shares, (c) all outstanding warrants or other rights to purchase shares (on an as-exercised basis), (d) other convertible securities (on an as-converted basis), and (such aggregate number of shares described in clauses (a) through (d) is hereafter referred to as the “Fully Diluted Capitalization”), as of the Effective Date. Company shall have obtained the proper corporate approvals to issue the shares to Wistar as of the Effective Date. 
 11

 
 
 (ii)               Dilution Protection.  In partial consideration of the licenses granted hereunder, from the Effective Date through the date by which Company has cumulatively raised or expended at least *** U.S. dollars ($*** USD) (the “Dilution Protection Cap”), Company will issue to Wistar, from time to time and at no additional consideration, such additional number of shares of Company as will cause Wistar to continue to hold in the aggregate five percent (5%) of the total shares of Company on a fully diluted basis, assuming the exercise, conversion and exchange of all outstanding securities of Company for or into shares. For the avoidance of doubt, the Dilution Protection Cap specifically excludes non-cash charges incurred by Company. Within forty-five  (45) days of the end of each Fiscal Quarter of the Company’s October 31 year end Fiscal Year, Company shall provide Wistar with a report that shows total financial proceeds or direct expenditures that are to be counted toward the Dilution Protection Cap for the previous Fiscal Quarter. 
 (iii)             Restrictions on Transferability.  The Shares shall not be transferable in the absence of a registration under the Securities Act of 1933, as amended, or an exemption therefrom. Company shall be entitled to give stop transfer instructions to the transfer agent with respect to the Shares in order to enforce the foregoing restrictions. The Shares shall also be subject to the restrictions on transfer set forth in the Equity Documents only so long as all other holders of common stock of the Company are subject to similar restrictions. 
 (iv)             Restrictive Legend.  Each certificate representing the Shares shall bear substantially the following legends (in addition to any legends required under applicable securities laws):
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT purposes only AND HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATIONUNDER THE SECURITIES ACT OF 1933, AS AMENDED. THE SHARES MAY NOT BE OFFERED, SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM. 
 (v)               Preemptive Rights.  If the Company has raised or expended the Dilution Protection Cap limit and the Company  proposes to sell any equity securities or securities that are convertible into equity securities of the Company (collectively, “Equity Securities”) in a financing, then Wistar and/or its Assignee (as defined below) will have the right to purchase up to that portion of the Equity Securities that equals Wistar’s then current, fully diluted percentage ownership of the Company on the same terms and conditions as are offered with respect to such Equity Securities sold in such financing, provided that upon notification to Wistar that financing is conducted with general terms, Wistar or its Assignee will have five (5) business days to determine whether it will participate in purchasing Equity Securities as permitted under this Section. For the purposes of this clause 3.1.2(v) 1.1, the term “Assignee” means (1) any entity to which Wistar’s preemptive rights have been assigned either by Wistar or another entity, or (2) any entity that is controlled by Wistar.
 12

 
 
 (vi)             Right of Participation. From the date hereof until the date on which the Dilution Protection Cap has been exceeded, upon the sale by the Company of common stock or securities convertible or exercisable into common stock for cash consideration (other than for an acquisition or strategic transaction, a “Subsequent Financing”), Wistar shall have the right to participate in up to an amount of the Subsequent Financing equal to five percent (5%) of the Subsequent Financing (the “Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent Financing. The Company shall provide at least ten (10) business days’ prior notice to Wistar of a Subsequent Financing. Such notice shall include a description of the proposed terms of the Subsequent Financing and the amount of proceeds intended to be raised thereunder. If Wistar desires to participate in the Subsequent Financing, Wistar shall provide written notice to the Company by not later than 5:30 p.m. (New York City time) on the fifth (5th) business day after notice was received. Such notice shall include the amount of such Wistar’s participation, and shall represent and warrant that Wistar has such funds ready, willing, and available for investment on the terms set forth in the Subsequent Financing notice.  If the Company receives no such notice from Wistar as of such fifth (5th) business day, Wistar shall be deemed to have notified the Company that it does not elect to participate  If Wistar elects to not participate in a Subsequent Financing, such election shall not waive Wistar’s Dilution Protection rights under Section 3.1.2(ii).  
 3.2                       Royalties.   
 3.2.1.      Company shall pay to Wistar a running royalty on Net Sales of all Licensed Products in accordance with the table set forth below within thirty (30) days following the last day of the Calendar Quarter in which such royalty accrues:
  	 Royalty Percentage
	 for that portion of aggregate Net Sales of Licensed Products: 

	 ***
	 ***

	 ***
	 ***

	 ***
	 ***

  
 3.2.2.      In the event that Company, in order to exploit the licenses granted to it under this Agreement in any country, actually makes running royalty payments on net sales of a Licensed Product to one or more third parties (“Third Party Payments”) as consideration for a license to patent rights held by such parties that dominate the Licensed Patents in such country, Company shall have the right, on a country-by-country basis, to reduce the royalty payments otherwise due to Wistar under this Section 3.2 for such Licensed Product by fifty percent (50%) of the Third Party Payments actually made in the relevant reporting period; provided, however, (a) Company is entitled to offset the royalties owing to the third party on such net sales by means of an equivalent stacking provision, or one more favorable to Company than the above, (b) in no event shall the royalties due to Wistar for any Licensed Product in any country be reduced to less than fifty percent (50%) of the royalties otherwise payable under Section 3.2.1, and 
 13

 
 
  (c) any Third Party Payments that are not offset during the royalty reporting period when such payments are actually made shall not be creditable against payments arising in subsequent royalty reporting periods. As used in this Section 3.2.2 ̧ a Licensed Patent is dominated if it cannot be practiced without infringing a valid claim of an issued patent. If Company determines that Third Party Payments are necessary, Company will notify Wistar of said determination in writing within thirty (30) calendar days of reaching said determination. 
 3.3                       Royalty Term.  The period during which the royalties set forth in Section 3.2.1 shall be payable, on a Licensed Product-by-Licensed Product basis, shall commence on the Effective Date and continue until the later of (i) the expiration or termination of the last to expire Valid Claim of a patent covering the making, having made, use, sale, offering for sale, exportation or importation of such Licensed Product, and (ii) the fifteenth (15th) anniversary of the First Commercial Sale of such Licensed Product (each such period, a “Royalty Term”).
 3.4                       Minimum Annual Royalties.
 3.4.1.      Company shall pay to Wistar as a non-refundable advance against royalties during the ensuing year, a minimum annual royalty of *** U.S. dollars ($*** USD) due on January 1st following the First Commercial Sale of the Licensed Product that is subject to the royalties set forth in Section 3.2.1 and on each January 1st thereafter (the “Minimum Annual Royalties”).
 3.4.2.      Minimum Annual Royalties shall be available for credit against royalties only during the year in which such Minimum Annual Royalties are paid and shall not be available for credit in any other year. 
 3.5                       Non-Royalty Sublicensing Income.  Company shall pay to Wistar *** percent (***%) of Non-Royalty Sublicensing Income within thirty (30) days following the last day of the Calendar Quarter in which such Non-Royalty Sublicensing Income is paid to or received by the Company accrues in a form that can be chosen at the Wistar’s option, including the form in which Company received or was paid such Non-Royalty Sublicensing Income, provided that if Wistar elects a form other than the form in which the Company received or was paid Non-Royalty Sublicensing Income, that Wistar and the Company will share equally the cost of converting the Non-Royalty Sublicensing Income received  to the form that Wistar elects.
 3.6                       Maintenance Fees.  In further consideration of the license granted to Company hereunder, Company shall pay to Wistar nonrefundable, non-creditable annual maintenance fees as follows until the date of the First Commercial Sale of a Licensed Product:
 (i)                 *** U.S. dollars ($*** USD) upon the third and fourth anniversaries of the Effective Date;  
 (ii)               *** U.S. dollars ($*** USD) upon the fifth and sixth anniversaries of the Effective Date; and
 (iii)             *** U.S. dollars ($*** USD) upon the seventh anniversary of the Effective Date and on each anniversary of the Effective Date thereafter.
 14

 
 
  
 3.7                       Milestone Payments.  
 3.7.1.      Company shall pay to Wistar milestone payments in the following amounts within thirty (30) days of each of the following events:
 (i)                 *** U.S. dollars ($*** USD) upon the enrollment of the first patient in a Phase I or a Phase I/II Clinical Trial by Company, its Affiliates or any Sublicensee for *** Licensed Products;
 (ii)               *** U.S. dollars ($*** USD) upon the enrollment of the first patient in a Phase II Clinical Trial by Company, its Affiliates or any Sublicensee for *** Licensed Products (for the avoidance of doubt, Phase II Clinical Trials include Phase IIa and Phase IIb Clinical Trials); 
 (iii)             *** U.S. dollars ($*** USD) upon the enrollment of the first patient in a Phase III Clinical Trial or other pivotal Clinical Trial by Company, its Affiliates or any Sublicensee for *** Licensed Products;
 (iv)             *** U.S. dollars ($*** USD) upon initial receipt by Company, its Affiliates or any Sublicensee of Regulatory Approval for *** Licensed Products;
 (v)               *** U.S. dollars ($*** USD) upon the First Commercial Sale of each Licensed Product by Company, its Affiliates or any Sublicensee; and 
 (vi)             *** U.S. dollars ($*** USD) upon Company, its Affiliates and any Sublicensee achieving aggregate Net Sales of *** U.S. dollars ($*** USD) for Licensed Products. 
 3.7.2.      These milestone payments shall not be credited against or otherwise reduce royalties or other compensation provided for in this Agreement. For clarity, each time a milestone is achieved with respect to a Licensed Product, then any milestone payments with respect to earlier milestones that have not yet been paid will be due and payable together with the milestone payment for the milestone that is actually achieved. For additional clarity, milestones are due and payable on Licensed Products and on products that, upon Regulatory Approval, would become Licensed Products.  
 3.8                       Reports.  Company shall deliver to Wistar within thirty (30) days after the end of each Calendar Quarter, a complete and accurate report for that Calendar Quarter in the form specified in Schedule IIattached hereto, certified by a senior financial officer of Company.
 3.9                       Payments.  All dollar amounts referred to in this Agreement are expressed in United States dollars.  Liability for royalties on Licensed Products manufactured by Company, its Affiliates or any Sublicensee shall accrue when a Licensed Product is sold, used or otherwise disposed of; provided that, if a partial payment is made, a royalty shall accrue pro rata to such partial payment.  Any payments not paid to Wistar when due hereunder shall accrue interest from the due date until paid at a rate equal to the lesser of six percent (6%) per annum or the maximum interest rate allowed by applicable law, whichever is greater. Notwithstanding the foregoing, Wistar shall be entitled to treat any such late payment as a material breach of this Agreement, notwithstanding the payment of interest.  
 15

 
 
  
 3.9.1.      All payments due hereunder shall be payable in U.S. dollars by a check made payable to the order of “The Wistar Institute of Anatomy and Biology” and drawn on a U.S. bank, or by wire transfer (ACH), and sent to the following:
  	 For Payment By ACH/Wire:
	  
	 For Payment By Check (Mail To):

	 ***
	  
	 ***

  
 3.9.2.      Currency.  Where it is necessary to convert the amount of royalties due from another currency into U.S. dollars, conversion shall be made using one of the following rates as published or issued on the last business day of the Calendar Quarter in which such royalties have accrued: 
 (i)                 the spot rate or the mean of the buy and sell spot rates, if no single rate is published, as published by “The Wall Street Journal;” or 
 (ii)               at the currency conversion rate published or issued at the close of business by a third party selected by Company, provided that Company has obtained Wistar’s prior written consent to use such third party rate for calculation of royalties due to Wistar.
 3.9.3.      Fees and Taxes.  All payments under this Agreement shall be made without any deduction or withholding for or on account of any tax, except as expressly permitted in this Agreement.  If any income or other taxes, withholdings or other deductions required by applicable law to be withheld or deducted from any of the payments made by or on behalf of Company hereunder (“Withholding Taxes”) are imposed on a payment by any applicable law, Company shall pay such Withholding Taxes to the proper taxing authority and, if available, evidence of such payment shall be secured and sent to Wistar within one (1) month of such payment.  In the case of any Withholding Taxes imposed with respect to any payment hereunder, Company shall pay to Wistar an additional amount as is necessary to ensure that the amount actually received by Wistar with respect to such payment, free and clear of the Withholding Taxes (including any such Withholding Taxes imposed on such additional amount), shall equal the amount of the payment that would have been made if no such Withholding Taxes had applied.
 3.10                   Records.  Company shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate books and records of all Licensed Products sold which enable the royalties and other amounts payable hereunder to be verified.  Upon reasonable prior notice to Company, its Affiliates or any Sublicensee and during normal business hours, an auditor paid for and selected by Wistar may inspect such books and records of Company, its Affiliates and Sublicensees for the three (3) year period immediately preceding the date of inspection to verify the correctness of the reports given to Wistar under Section 3.8.  If Wistar’s auditor determines that Company, its Affiliate or any Sublicensee has underpaid royalties and other amounts payable by ten percent (10%) or more, Company shall pay the costs and expenses of the audit and the right of inspection shall extend to books and records for periods prior to such three (3) year period.  Nothing contained in this Section 3.10 shall shorten the period established by any applicable statute of limitations.
 16

 
 
  
 Article 4 - CERTAIN OBLIGATIONS OF COMPANY 
 4.1                       Diligent Efforts.  Company, acting itself and/or through its Sublicensees, (i) shall use best efforts to develop Licensed Products and to bring Licensed Products to market through a thorough, vigorous and diligent program for exploitation of the Licensed Patents and Licensed Technical Information and to continue active, diligent marketing efforts for Licensed Products throughout the Term, consistent with sound and reasonable business practices, and (ii) shall endeavor to keep Licensed Products reasonably available to the public.
 4.2                       Performance Milestones.  In addition to Company’s diligence obligations in Section 4.1, Company, acting itself and/or through its Sublicensees, shall perform or fulfill the following obligations (the “Performance Milestone(s)”) by the dates set forth below (the “Performance Milestone Date(s)”):
 4.2.1.      Within forty-five (45) days after the Effective Date, Company shall furnish Wistar with a written research and development plan describing the major tasks to be achieved in order to complete preclinical testing necessary to support clinical testing of Licensed Products, a timeline for achievement of such tasks, and an estimate of the number of staff and financial and other resources to be devoted to such preclinical testing, which for the avoidance of doubt, is the Company’s preclinical testing plan with the H. Lee Moffitt  Cancer Center and Research Institute, Inc.(“Commercialization Plan”);
 4.2.2.      ***;
 4.2.3.      ***;
 4.2.4.      ***; and 
 4.2.5.      ***.
 4.3                       Diligence Failure.  ***
 4.4                       Diligence Reports.
 4.4.1.      Company shall provide Wistar on December 1 of each year with written reports, setting forth in such detail as Wistar may reasonably request, the progress of the development, evaluation, testing and commercialization of the Licensed Products, including information on (i) the progress of matters related to Regulatory Approvals and (ii) progress made toward the objectives set forth in the Commercialization Plan, including any progress of securing Sublicenses and any progress of Sublicensees developing Licensed Products.  Company also shall notify Wistar within thirty (30) days after the First Commercial Sale of a Licensed Product by Company, its Affiliates or any Sublicensee.
 17

 
 
  
 4.4.2.      In order that Wistar may provide the United States Department of Health and Human Services with information required under the Funding Agency Interest, Company shall, at its cost, prepare and provide written annual reports to Wistar containing sufficient information to enable the Department of Health and Human Services to evaluate Company’s progress in the development of Licensed Products, but shall not contain information considered proprietary or confidential by Company.  Such reports shall be provided no later than January 1st of each year.
 4.5                       Compliance with Laws.
 4.5.1.      Company shall (a) comply with all applicable laws, rules and regulations pertaining to the development, testing, manufacture, marketing, import or export of the Licensed Products; and (b) not employ, contract with or retain any Person directly or indirectly if such Person is: (i) excluded from a Federal health care program as outlined in Sections 1128 and 1156 of the Social Security Act (see the Office of Inspector General of the Department of Health and Human Services List of Excluded Individuals/Entities at http://www.oig.hhs.gov/fraud/exclusions/exclusions_list.asp), (ii) debarred by any Health Authority, including (but not limited to) by the FDA under 21 U.S.C. 335a (see the FDA Office of Regulatory Affairs Debarment List at http://www.fda.gov/ICECI/EnforcementActions/FDADebarmentList/default.htm), or (iii) excluded from contracting with the federal government (see the Excluded Parties Listing System at www.sam.gov).  
 4.5.2.      Without limiting Section 4.5.1, Company acknowledges that the transfer and use by foreign nationals of certain commodities and technical data is subject to U.S. laws and regulations controlling the export and use by foreign nationals of such commodities and technical data, including the Arms Export Control Act, the International Traffic in Arms Regulations (“ITAR”), the Export Administration Regulations (“EAR”) and the laws and regulations implemented by the Office of Foreign Assets Control, U.S. Department of the Treasury (“OFAC”).  These laws and regulations, among other things, prohibit or require a license for the export or use by foreign nationals of certain types of technical data to specified countries.  Company shall comply with all such applicable U.S. laws and regulations.
 4.5.3.      Company shall be solely responsible for any violation of the provisions of this Section 4.4 by Company, its Affiliates or any Sublicensees.
 4.5.4.      Each party hereunder agrees that it has not and will not, either directly or indirectly, engage in bribery, or offer, or promise, or authorize to pay or make any improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political or philanthropic contribution, anything of value, or any other perceived benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each party hereunder agrees that it shall not take any action that would cause the other parties to be in violation of such Anti-Corruption Laws.  Any adjudicated breach of this Section 4.5.4 by a party shall allow the other parties hereunder to immediately terminate this Agreement.
 18

 
 
  
 4.5.5.      To the extent required by the Funding Agency Interest, all Licensed Products to be used or sold in the United States shall be manufactured substantially in the United States, and Company shall take such actions as are necessary to assure that it and its Affiliates and Sublicensees comply with the obligations imposed by this Section4.54.5.
 4.6                       Conflict of Interest.  Company acknowledges that Wistar’s employees and staff members are subject to the applicable policies of Wistar, including policies regarding conflicts of interest, intellectual property and other matters.  Company shall not enter into any oral or written agreement with such employee or staff member which conflicts with any such policy.
 4.7                       Patent Notices.  Company shall mark the Licensed Products sold in the United States with all applicable patent numbers.  All Licensed Products shipped to and/or sold in other countries shall be marked and labeled in such a manner as to conform with all applicable laws of the country where the Licensed Products are sold.
 4.8                       Regulatory Approvals.  Company shall be responsible for obtaining and maintaining, at its cost and expense, all Regulatory Approvals.
 4.9                       Information Rights. The Company shall furnish the following reports to Wistar during the term of this Agreement: (1) Within ninety (90) days of the Company’s fiscal year end, the Company shall provide to Wistar an unaudited balance sheet and statement of operations for such fiscal year; and (2) within forty-five (45) days following the end of the Company’s first, second and third fiscal quarters, the Company shall provide to Wistar an unaudited balance sheet and statement of operations for such fiscal quarter.  The reports provided by the Company to Wistar shall be in such form as determined in the sole discretion of the Company and shall be consistent with the reports that ITUS prepares for each of ITUS’ consolidated subsidiaries when preparing ITUS’ annual and quarterly financial statements.
 4.10                   Stockholders’ Agreement. If at any time, the Company enters into a stockholder’s agreement affording rights to a stockholder of the Company, Wistar shall have the option to become a party to such agreement.
 19

 
 
  
 Article 5 - REPRESENTATIONS AND WARRANTIES
 5.1                       Representations and Warranties.  
 5.1.1.      Company represents and warrants that it is a corporation, duly organized, validly existing and in good standing under the laws of the State of Delaware, and has all requisite corporate power and authority to execute, deliver and perform this Agreement; and Wistar represents and warrants that it is a nonprofit corporation, duly organized, validly existing and in good standing under the laws of the Commonwealth of Pennsylvania, and has all requisite corporate power and authority to execute, deliver and perform this Agreement.
 5.1.2.      In addition, Company represents and warrants to Wistar (a) that the issuance and delivery to Wistar of the Shares have been duly authorized by all requisite corporate action of Company and Company has full corporate power and lawful authority to issue and deliver the Shares on the terms and conditions contemplated herein, and when so issued and delivered, the Shares shall be validly issued and outstanding, fully paid and nonassessable, with no personal liability attaching to the ownership thereof, and not subject to preemptive or any similar rights of the stockholders of Company or any liens or encumbrances arising through Company; and (b) that (i) the authorized capital stock of Company consists of  5,000  shares of common stock, of which 950 are issued and outstanding, (ii) there are no outstanding options, warrants, rights (including conversion or preemptive rights), or agreements for the purchase or acquisitions from the Company of any shares of Company’s capital stock, (iii) no officer, director or stockholder of the Company or member of his or her immediate family are currently a party to any contract or arrangement (or has any interest in any entity that is a party to any contract or arrangement) with the Company (other than customary employment and equity investment agreements) or is indebted to the Company, nor is the Company indebted (or committed to make loans or extend or guarantee credit) to any of such individuals, and (iv) the Company has no liability or obligation, absolute or contingent (individually or in the aggregate), except obligations and liabilities incurred in the ordinary course of business, none of which, individually or in the aggregate, are material.
 5.1.3.      Company and Wistar each represent and warrant to the other that this Agreement, when executed and delivered by a party to this Agreement, shall be the legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms. 
 5.1.4.      Wistar  Representations and Warranties. Wistar represents and warrants that, to its knowledge   (a)  it is the sole and exclusive legal and beneficial owner of the entire right, title, and interest in and to the Licensed Patents, and is the record owner of all patent applications and issued patents that are Licensed Patents; (b) it has not granted any licenses or other contingent or non-contingent right, title, or interest under or relating to Licensed Patents, and is not under any obligation, that conflicts with this Agreement, including any of its  representations, warranties, or obligations, or Company’s rights or licenses hereunder;  (c) there are no encumbrances, liens, or security interests involving any Licensed Patent; 
 20

 
 
   (d)   there is no settled, pending, or threatened litigation alleging the unpatentability, invalidity, misuse, unregisterability, unenforceability, or noninfringement of, or error in any Licensed Patent challenging Wistar's ownership of, or right to practice or license, any Licensed Patent, or alleging any adverse right, title, or interest with respect thereto; and (e)it  has no knowledge of any factual, legal, or other reasonable basis for any litigation described  in this Section and has not received any written, oral, or other notice of any litigation described in this Section.  This paragraph expressly does not make any representations and warranties regarding any allegations as to patentability made in unrebutted communications from any patent office as of the Effective Date of this Agreement.  Wistar has not brought or threatened any claim against any third party alleging infringement of any Licensed Patent, nor, to its knowledge, is any third party infringing or, to its knowledge, preparing or threatening to infringe any patent, or practicing any claim of any patent application, included as a Licensed Patent.
 Article 6 - LIMITATION ON LIABILITY AND INDEMNIFICATION
 6.1                       Limitation on Liability.  IN NO EVENT SHALL WISTAR, ITS CURRENT AND FORMER TRUSTEES, MANAGERS, OFFICERS, AGENTS, EMPLOYEES, FACULTY, PERSONNEL, STAFF, STUDENTS OR VISITING SCIENTISTS BE LIABLE TO COMPANY, ITS SUCCESSORS, ASSIGNS, AFFILIATES, SUBLICENSEES OR THIRD PARTY FOR ANY LOSS OF PROFITS, LOSS OF BUSINESS, INTERRUPTION OF BUSINESS, OR FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, WHETHER UNDER THIS AGREEMENT OR OTHERWISE, EVEN IF SUCH PERSON HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS. WISTAR SHALL NOT BE LIABLE TO COMPANY, ITS SUCCESSORS, ASSIGNS, AFFILIATES, SUBLICENSEES OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM ON ACCOUNT OF, OR ARISING FROM, THE USE OF THE LICENSED PATENTS OR LICENSED TECHNICAL INFORMATION OR THE MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS OR ANY OTHER MATERIAL OR ITEM DERIVED FROM ANY OF THE FOREGOING.  
 6.2                       Exclusion of Consequential and Other Direct Damages.  To the fullest extent permitted by Law, Company shall not be liable to Wistar for any injury to or loss of goodwill, reputation, business production, revenues, profits, anticipated profits, contracts, or opportunities (irrespective of how these are classified as damages), or for any consequential, incidental, indirect, exemplary, special, punitive, or enhanced damages, whether arising out of breach of contract, tort (including negligence), or otherwise (including the entry into, performance or breach of this Agreement), regardless of whether such damage was foreseeable and whether or not the other party has been advised of the possibility of such damages..  Exclusion of Consequential and Other Direct Damages. To the fullest extent permitted by Law, Company shall not be liable to Wistar for any injury to or loss of goodwill, reputation, business production, revenues, profits, anticipated profits, contracts, or opportunities (irrespective of how these are classified as damages), or for any consequential, incidental, indirect, exemplary, special, punitive, or enhanced damages, whether arising out of breach of contract, tort (including negligence), or otherwise (including the entry into, performance or breach of this Agreement), regardless of whether such damage was foreseeable and whether or not the other party has been advised of the possibility of such damages.
 21

 
 
  
 OTHER THAN AS SET FORTH IN SETION 5.1.4, THE LICENSED PATENTS AND LICENSED TECHNICAL INFORMATION ARE PROVIDED ON AN “AS IS” BASIS AND WISTAR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE LICENSED PATENTS, LICENSED TECHNICAL INFORMATION OR ANY LICENSED PRODUCTS INCLUDING REPRESENTATIONS OR WARRANTIES OF COMMERCIAL UTILITY, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, VALIDITY OR ENFORCEABILITY OF THE LICENSED PATENTS, OR THAT THE USE OF THE LICENSED PATENTS, LICENSED TECHNICAL INFORMATION, LICENSED PRODUCTS OR ANY MATERIALS OR ITEMS DERIVED FROM ANY OF THE FOREGOING WILL NOT INFRINGE ANY PATENT, COPYRIGHT OR TRADEMARK OR OTHER PROPRIETARY OR PROPERTY RIGHTS OF OTHERS.  WISTAR EXPRESSLY DISCLAIMS ANY WARRANTY THAT THE LICENSED PATENTS OR LICENSED TECHNICAL INFORMATION ARE FREE FROM THE RIGHTFUL CLAIMS OF ANY THIRD PARTY.  
 6.3                       Indemnification.  Company shall indemnify and hold harmless Wistar, its current and former trustees, managers, officers, agents, employees, faculty, personnel, staff, students and visiting scientists (collectively and individually, the “Indemnified Parties” or “Indemnified Party”), from and against any and all liability, loss, damage, action, claim or expense (including attorney’s fees) suffered or incurred by the Indemnified Parties due to claims by a Person not a party to this Agreement (individually, a “Liability” and collectively, the “Liabilities”) which result from or arise out of (a) this Agreement, the license granted hereunder and any Sublicense granted pursuant to this Agreement, (b) the development, use, manufacture, promotion, sale or other disposition of the Licensed Patents, Licensed Technical Information, or any Licensed Products by Company, its Affiliates, assignees, Sublicensees, vendors or other third parties, (c) the breach of any representation, warranty, or covenant of this Agreement by Company, or of a Sublicense by any Sublicensee, or (d) the successful enforcement by an Indemnified Party of its rights under this Section 6.2.  Wistar shall indemnify and hold harmless Company from and against any and all liability, loss, damage, action, claim or expense (including attorney’s fees) suffered or incurred by the Indemnified Parties due to the breach of any representation, warranty, or covenant of this Agreement by Wistar.  This indemnification obligation shall apply regardless of the negligence of the Indemnified Party. Without limiting the foregoing, Company shall indemnify and hold harmless the Indemnified Parties from and against any Liabilities resulting from 
 22

 
 
  
 6.3.1.      any product liability or other claim of any kind related to the use of a Licensed Product manufactured, sold or otherwise disposed of by Company, its assignees, Affiliates, and Sublicensees, vendors or other third parties;
 6.3.2.      any claim that the Licensed Patents, Licensed Technical Information or the design, composition, manufacture, use, sale or other disposition of any Licensed Product infringes or violates any patent, copyright, trademark or other intellectual property rights of any third party; or
 6.3.3.      Clinical Trials or studies conducted by or on behalf of Company, its Affiliate or any Sublicensee relating to the Licensed Products, including any claim by or on behalf of a human subject of any such Clinical Trial or study, any claim arising from the procedures specified in any protocol used in any such Clinical Trial or study, any claim of deviation, authorized or unauthorized, from the protocols of any such Clinical Trial or study, and any claim resulting from or arising out of the manufacture or quality control by a third party of any substance administered in any Clinical Trial or study.
 6.4                       Procedures.  The Indemnified Party shall promptly notify Company of any claim or action giving rise to a Liability subject to the provisions of Section ?6.2.  Company shall have the right to defend any such claim or action, at its cost and expense, with counsel reasonably satisfactory to Wistar.  Company shall not settle or compromise any such claim or action in a manner that (i) imposes any restrictions or obligations on any Indemnified Party without such Indemnified Party’s prior written consent, or (ii) grants any rights to the Licensed Patents without Wistar’s prior written consent.  If Company fails or declines to assume the defense of any such claim or action within thirty (30) days after notice thereof, Wistar may assume the defense of such claim or action for the account and at the risk of Company, and any Liability related thereto shall be conclusively deemed a Liability of Company.  Company shall pay promptly to the Indemnified Party any Liabilities to which the foregoing indemnity related, as incurred.  The indemnification rights of the Indemnified Parties contained herein are in addition to all other rights which such Indemnified Parties may have at law or in equity or otherwise.
 6.5                       Insurance.  Company shall maintain general liability and product liability insurance as follows: 
 6.5.1.      beginning with the Effective Date and for ten (10) years after the date of expiration or termination of this Agreement, general liability insurance in amounts not less than one million U.S. dollars ($1,000,000 USD) per incident and two million U.S. dollars  ($2,000,000 USD) in the aggregate; and 
 6.5.2.      beginning with the commencement of Clinical Trials and for ten (10) years after the date of expiration or termination of this Agreement, product liability insurance in amounts not less than ten million U.S. dollars ($10,000,000 USD) per incident and ten million dollars U.S. ($10,000,000 USD) in the aggregate. 
 23

 
 
  
 6.5.3.      Such insurance shall be issued by an insurance company rated AA or better and naming Wistar as an additional insured.  The minimum insurance amounts specified herein shall not be deemed a limitation on Company’s indemnification liability under this Agreement.  Company shall provide Wistar with copies of endorsements to such policies.  Company shall notify Wistar at least thirty (30) days prior to cancellation of any such coverage.  To the extent Company is awarded a business interruption insurance award which provides for lost profits, Company shall pay to Wistar reasonable royalties for the period of the award which payment shall be based upon projections of Net Sales of Licensed Products and the history of royalties paid hereunder for such Net Sales.
 6.5.4.      Company shall require any Sublicensee to maintain insurance under the same terms as set forth in Sections 6.4.16.4.16.5.1 and 6.4.26.4.2 above, including naming Wistar as an additional insured.
 Article 7 - PATENTS AND INFRINGEMENT
 7.1                       Prosecution of Patents.
 7.1.1.      Subject to Section 7.1 and its subsections, Wistar shall have the exclusive responsibility and control over the Prosecution of the Licensed Patents.  Upon execution of this Agreement, Company shall reimburse Wistar for Patenting Costs incurred by Wistar prior to the Effective Date and not previously reimbursed by ITUS or Company under the Option (“Past Patenting Costs”).  With respect to any Patenting Costs incurred by or on behalf of Wistar after the Effective Date, Company shall remit payment of such Patenting Costs within thirty (30) days after Company receives invoices for same.  Notwithstanding the foregoing, at least sixty (60) days before a particular action is required for the protection of certain rights comprising the Licensed Patents (the “Bar Date”), Wistar shall have the right to request advance payment of reasonable estimated Patenting Costs for such action if such estimated Patenting Costs are at least twenty thousand U.S. dollars  ($20,000 USD), and Company shall be obligated to pay the amount of such estimated Patenting Costs no less than thirty (30) days before the Bar Date.  So long as Wistar’s request is timely made, Wistar shall have no obligation to take or have taken such action, and no liability for failing to take such action, to protect the Licensed Patents at issue, unless the estimated Patenting Costs are timely paid by Company, even if the result is the irrevocable loss of rights.
 7.1.2.      For each patent application and patent under the Licensed Patents, Wistar shall:  prepare, file, and prosecute such patent application: maintain such patent; pay all fees and expenses associated with its activities pursuant to Section 7.1; keep Company currently informed of the filing and progress of all material aspects of the prosecution of such patent application and the issuance of patents from any such patent application; consult with Company concerning any decisions which could affect the scope or enforcement of any issued claims or the potential abandonment of such patent application or patent; and notify Company in writing of any additions, deletions, or changes in the status of such patent or patent application.
 24

 
 
 7.1.3.      Company and Wistar shall mutually determine the jurisdictions, other than the United States, where the Licensed Patents shall be Prosecuted.  If Company declines to pay for Patenting Costs in any jurisdiction, Wistar may do so at its cost and expense but such patents and the subject matter of any application relating thereto shall be excluded from the definition of Licensed Patents.
 7.1.4.      If Wistar elects not to Prosecute any patent or patent application included in the Licensed Patents, it shall notify Company at least sixty (60) days prior to taking, or not taking, any action which would result in abandonment, withdrawal, or lapse of such patent or patent application. Such patent application or patent shall no longer be a Licensed Patent and Company shall not have any further royalty or other payment obligation for such patent application or patent. Company shall then have the right to Prosecute such patent or patent application at its own cost and expense in Wistar’s name.
 7.1.5.      Each party shall cooperate with the other party to execute all lawful papers and instruments and to make all rightful oaths and declarations as may be necessary in the Prosecution of all such patents and other applications and protections referred to in this Article 7.
 7.1.6.      All non-public information exchanged between the parties or between Wistar’s patent counsel and Company regarding Prosecution and enforcement of the Licensed Patents, and all shared information regarding analyses or opinions of third party intellectual property, shall be deemed Confidential Information. In addition, the parties acknowledge and agree that, with regard to Prosecution and enforcement of the Licensed Patents, the interests of the parties as licensor and licensee are to obtain the strongest patent prosecution possible, and as such, are aligned and are legal in nature. The parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Licensed Patents or the Confidential Information, including privilege under the common interest doctrine and similar or related doctrines.
 7.2                       Ownership.  Wistar shall retain all right, title and interest in and to the Licensed Patents, Wistar Confidential Information and Licensed Technical Information regardless of which party Prosecutes the patents, subject to the express license granted to Company under Article 2 hereof.
 7.3                       Infringement.  
 7.3.1.      Each party shall promptly notify the other party in writing of any infringement or possible infringement of any Licensed Patent in the Licensed Field.  Company shall have the first right, but not the obligation, to prosecute such infringement in the Licensed Field at its own expense.  Company shall use the same degree of diligence in prosecuting such infringement as it uses or would use in prosecuting infringement of its own patent rights.  In the event Company elects to prosecute such infringement, Wistar shall cooperate with Company, at Company’s reasonable request and Company’s sole expense, in any such infringement action. Company shall reimburse Wistar for any such expense within thirty (30) days after Company’s receipt of invoice for the same.
 25

 
 
 Company shall keep Wistar informed of the status and progress of any action brought under this Section 7.3 and Company shall not settle or compromise any such suit in a manner that imposes any obligations or restrictions on Wistar or grants any rights to the Licensed Patents, Wistar Confidential Information or Licensed Technical Information without Wistar’s prior written consent.  Prior to commencing any such infringement action, Company shall consult with Wistar and shall consider the views of Wistar regarding the advisability of the proposed action and its effect on the public interest.  If Company exercises its right to bring an infringement action against the alleged infringer, Company shall be obligated to defend any cross claim or counterclaim or action for declaratory judgment related to the Licensed Patents or Licensed Product.
   
 7.3.2.      If Company fails to prosecute such infringement within ninety (90) days after receiving notice thereof, Wistar shall have the right, but not the obligation, to prosecute such infringement at its own expense.  In such event, Company shall cooperate with Wistar, at Company’s sole expense.  Wistar shall not settle or compromise any such suit in a manner that imposes any limitations or restrictions on the rights granted to Company in Article 2 hereof without Company’s written consent.  In any such settlement or compromise, consideration will be given in good faith to granting the infringer a Sublicense under the Licensed Patents in the Licensed Field on appropriate terms.
 7.3.3.      Any recovery obtained by the prosecuting party as a result of such proceeding, by settlement or otherwise, shall be applied first to the prosecuting party, an amount equal to its costs and expenses of the litigation, with the remainder to be paid fifty percent (50%) to Wistar and fifty percent (50%) to Company.
 7.4                       Certain Notices.  Company shall notify Wistar at least sixty (60) days before Company uses or exports the Licensed Patents or any Licensed Product in or to any country outside the United States to allow Wistar to make any patent filings or to take other actions necessary to protect the Licensed Patents.
 7.4.1.      Patent Term Extension Obligations.  Company shall keep Wistar fully informed of Company’s and each Sublicensee’s progress toward Regulatory Approval for commercial sale of each Licensed Product with respect to each Licensed Patent hereunder.  Company shall assist Wistar in determining with respect to such Licensed Products if the Licensed Patents would be eligible for patent term extension pursuant to 35 U.S.C. §§156, and, as appropriate, applicable foreign patent laws (a “Patent Term Extension”).  Company acknowledges that time is of the essence with respect to submission of any application for Patent Term Extension.  Company shall give Wistar prompt oral notification when each of its or its Sublicensee’s Licensed Products with respect to each Licensed Patent have received permission (under the provision of law under which the applicable regulatory review occurred) for commercial marketing or use, and shall confirm such notification in writing within five (5) business days of receipt of written notice of marketing approval from the regulatory agency. Wistar shall consider in good faith any request by Company that it or they apply for Patent Term Extension.  Wistar shall have the right, but not the obligation, to apply for Patent Term Extension. 
 26

 
 
 At Wistar’s request, Company shall, in a timely manner, assist Wistar in preparing an application for Patent Term Extension in compliance with 35 U.S.C. §156 et seq., and, as appropriate, any applicable foreign patent laws.  Company and its Sublicensees shall cooperate fully with Wistar in preparing the applications for Patent Term Extension. Company agrees to join in such applications at Wistar’s request.  Company shall fully support such applications and shall provide such information as may be requested in support of such applications by Wistar or by the government.
 7.5                       Licensed Patent Challenges.  In the event that Company or a Sublicensee or any of their Affiliates directly or indirectly brings, or assists in bringing, a Patent Challenge, then (i) Company shall provide Wistar with at least sixty (60) days’ notice prior to taking any such action, (ii) the parties consent that Section 10.9 shall apply; (iii) Company shall pay all costs, fees and expenses associated with such Patent Challenge that are incurred by Wistar and its trustees, managers, officers, agents, employees, faculty, affiliated investigators, personnel, and staff, including attorneys’ fees and all costs associated with administrative, judicial or other proceedings, within thirty (30) days after receiving an invoice from Wistar for same; (iv) the exclusive licenses granted in this Agreement shall, as of the date of initiation of said challenge or opposition, automatically convert to a non-exclusive license for the remainder of the Term, and Wistar shall have the right to grant licenses under the Licensed Patents to third parties, subject to the then-existing non-exclusive license provided herein; (v) any fees, royalties, milestones or revenues payable to Wistar hereunder shall double in amount if and when any Licensed Patent survives the Patent Challenge such that it remains valid in whole or in part; and (vi) at any time after the Patent Challenge is brought, Wistar may, at its option, terminate this Agreement according to Section 9.2; provided that if any of subsections (i) through (vi) are held invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect any of the other said subsections.  Notwithstanding any provision of this Agreement to the contrary, Company shall not have the right to assume or participate in the defense, settlement or other disposition of such Patent Challenge through its status as a licensee under this Agreement, but shall pay associated costs, fees and expenses as provided in Section 7.5(iii).  The parties agree any challenge or opposition to a Licensed Patent by Company may be detrimental to Wistar, and that the above provisions shall constitute reasonable liquidated damages to reasonably compensate Wistar for any loss it may incur as a result of Company taking such action.
 Article 8 - CONFIDENTIALITY
 8.1                       Confidentiality.
 8.1.1.      “Wistar Confidential Information” means (i) the Licensed Technical Information; (ii) any information provided to Company in connection with Prosecution under this Agreement, and (iii) any information or material that is sent to Company by Wistar prior to or after the Effective Date of this Agreement and marked “Confidential” or when the confidential nature of such information or material is apparent from context and subject matter.  “Company Confidential Information” means (a) the Commercialization Plan, and (b) any reports prepared by Company and provided to Wistar pursuant to Sections  3.8, 4.4.1 and 4.9. The terms of this Agreement but not the existence of this Agreement, constitute the Confidential Information of both parties hereunder. “Confidential Information” means the Wistar Confidential Information and Company Confidential Information, as applicable.
 27

 
 
  
 8.1.2.      For the Term of this Agreement and a period of five (5) years thereafter, (a) Company shall maintain in confidence and shall not disclose to any third party any Wistar Confidential Information, and (b) Wistar shall maintain in confidence and shall not disclose to any third party any Company Confidential Information.  Each party shall take all reasonable steps to protect the Confidential Information of the other party with the same degree of care used to protect its own confidential or proprietary information.  Neither party shall use the Confidential Information of the other party for any purpose other than those contemplated by this Agreement. The foregoing obligations under this Section 8.1.2 shall not apply to:
 (i)                 information that is known to the receiving party or independently developed by the receiving party prior to the time of disclosure without use of or reference to the other party’s Confidential Information, in each case, to the extent evidenced by written records promptly disclosed to the furnishing party upon receipt of such Confidential Information;
 (ii)               information disclosed to the receiving party by a third party that has a right to make such disclosure;
 (iii)             information that becomes patented, published or otherwise part of the public domain as a result of acts by the furnishing party or a third party obtaining such information as a matter of right; or
 (iv)             information that is required to be disclosed by order of the FDA or similar authority or a court of competent jurisdiction or other government authority or agency; provided that the parties shall use their best efforts to obtain confidential treatment of such information by the agency, authority, or court.
 8.1.3.      Wistar shall not be obligated to accept, and assumes no institutional liability or responsibility for, Company Confidential Information that Company furnishes to any employee of Wistar other than its business or legal officers as provided in this Agreement.  If Company desires to furnish any Company Confidential Information to other employees of Wistar, Company shall so inform Wistar and Wistar shall decide whether such individual may receive some or all such Company Confidential Information and, if so, whether such individual shall sign a separate confidentiality agreement to govern the use and disclosure of such information.
 8.2                       Publication.  Company acknowledges that a basic objective of the research and development activities of Wistar is the generation of new knowledge and its expeditious dissemination.  To further that objective, Wistar retains the right, at its discretion, to demonstrate, publish or publicize a description of the Licensed Patents and Licensed Technical Information and any results of research conducted by Wistar with or relating to the Licensed Patents or Licensed Technical Information.  
 28

 
 
  
 8.3                       Use of Name; Publicity.  Company  or ITUS shall not directly or indirectly use Wistar’s name, or the name of any current or former trustee, manager, officer, agent, employee, faculty, affiliated investigator, personnel or staff thereof, without Wistar’s prior written consent. Subject to Section 8.1, neither party shall issue any press release or other public statements related to this Agreement without the prior written consent of an authorized representative of the other party as to each such use; provided that, the parties and ITUS may make the factual statement that Company has an exclusive license from Wistar under one or more of the patents or patent applications comprising the Licensed Patents,  and may discuss the terms of this License, intellectual property rights licensed under this license, payments made under this License, and regulatory status of any Licensed Products sold or for which regulatory approval is being sought to sell under this License, in filings of the Company or ITUS made with the Securities Exchange Commission (SEC) and in investor or road show presentations or on the Company’s or ITUS’s website.  Company will provide Wistar with any proposed SEC filings that are required to be provided for review at least 24 hours prior to filing or disclosure.  Company or ITUS will consider in good faith any requests of Wistar to redact information from the proposed filings, and Company or ITUS will be permitted to make its filings if otherwise in compliance with this Agreement upon expiration of the 24 hour notice period.  For the avoidance of doubt, Company or ITUS need not provide to Wistar any information that has previously been disclosed.   
 Article 9 - TERM AND TERMINATION
 9.1                       Term.  This Agreement shall remain in effect until the expiration of the Term unless earlier terminated as provided hereunder.
 9.2                       Termination by Wistar.  Upon the occurrence of any of the events set forth below, Wistar shall have the right to terminate this Agreement by giving written notice of termination, such termination to be effective with the giving of such notice, except that in the case of (iv), below, such termination shall occur automatically and without the necessity of notice by Wistar:
 (i)                 Company fails to pay any amount payable to Wistar within sixty (60) days after such amount becomes due;
 (ii)               Company fails to pay the Patenting Costs as required by Section 7.1.1 within sixty (60) days after such amount becomes due;
 (iii)             material breach by Company of any covenant or agreement (other than a breach referred to in clause (i) above) or any representation or warranty contained in this Agreement that is continuing sixty (60) days after Wistar gives Company written notice of such breach; notwithstanding the foregoing, if Company violates the laws, regulations or other legal authority in any jurisdiction relating to the development, use, storage, or marketing of the Licensed Products in a way that Wistar deems in its reasonable judgment to constitute a public safety or health hazard, Wistar may immediately terminate the license hereunder; 
 29

 
 
  
 (iv)             Company becomes subject to a Bankruptcy Event; 
 (v)               the dissolution or cessation of operations by Company; 
 (vi)             Company or any of its Affiliates or Sublicensees bring a Patent Challenge against Wistar, or assists others in bringing a Patent Challenge against Wistar (except as required under a court order or subpoena); or
 (vii)           Company fails to perform or fulfill its diligence obligations or any Performance Milestone in accordance with the requirements of Sections 4.1 or 4.2 and that failure is continuing ninety (90) days after Wistar gives Company written notice of such breach; and
 (viii)         Wistar’s right of termination in this Section 9.2 shall be in addition and without prejudice to, and shall not constitute a waiver of, any right of Wistar for recovery of any monies then due to it hereunder or any other right or remedy Wistar may have at law, in equity or under this Agreement.
 9.3                       Termination by Company.
 9.3.1.      Company may terminate this Agreement upon sixty (60) days’ prior written notice to Wistar if Wistar is in material breach of this Agreement and such material breach remains uncured for sixty (60) days after Company gives Wistar written notice of such breach.
 9.3.2.      In addition, if the Company is in good standing and has paid all monies due to Wistar under this Agreement, Company shall have the right to terminate this Agreement at any time after the third anniversary of this Agreement with or without cause upon ninety (90) days prior written notice to Wistar.
 9.3.3.      Company’s right of termination in this Section 9.3 shall be in addition and without prejudice to, and shall not constitute a waiver of, any right or remedy Company may have at law, in equity or under this Agreement.
 9.4                       Effect on Sublicenses.  Upon expiration or earlier termination of this Agreement for any reason, Company shall promptly notify its Sublicensees of such expiration or termination.  Upon notice by Wistar of its intent to terminate (or, if notice is not required, upon termination) of this Agreement, Company shall no longer have the authority to grant further Sublicenses. Any Sublicenses granted by Company under Section 2.4 of this Agreement shall terminate upon the expiration or earlier termination of this Agreement, unless Wistar, in its sole discretion, requests in writing that such Sublicense survive such expiration or termination and remain in force and effect, in which case such Sublicense shall be assigned to Wistar.
 30

 
 
  
 9.5                       Rights and Duties Upon Termination or Expiration.  Upon termination or expiration of this Agreement for any reason: 
 (i)                 all rights and licenses granted to Company under the terms of this Agreement shall terminate and nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such termination or expiration; 
 (ii)               all Confidential Information of the furnishing party shall be promptly returned or destroyed, at the furnishing party’s election; 
 (iii)             Company shall cease all production and sale of Licensed Products; 
 (iv)             final reports in accordance with Section 3.8 shall be submitted to Wistar; and 
 (v)               all royalties and other payments, including any unreimbursed Patent Costs, accrued or due to Wistar as of the termination or expiration date shall become immediately payable.  Notwithstanding the foregoing, after the effective date of termination of this Agreement, unless for breach by Company, Company and its Sublicensees may, for a period of six (6) months, sell all Licensed Products existing at the time of such termination or expiration, and complete Licensed Products in the process of manufacture at the time of such termination or expiration and sell the same, provided that Company shall comply with, and cause its Sublicensees to comply with, all of the terms of this Agreement, including, (a) Company shall pay to Wistar the running royalties and other payments as required hereinabove in Article 3, (b) insurance requirements as described in Section 6.5, and (c) Company shall submit the reports required by Section 3.8 hereof. 
 9.6                       Disposition of Company Developments.  In the event this Agreement is terminated, Wistar’s financial interest in and to the Licensed Patents may be harmed, due to lost patent term and other factors.  Therefore, in the event of termination of this Agreement prior to expiration of the Term, Company shall:
 (i)                 provide Wistar with access to and, at Wistar’s request, deliver to Wistar all documents, filings, data and other information in Company’s possession relating to any of the Licensed Patents or Licensed Products, including all records required by regulatory authorities to be maintained with respect to Licensed Products, all regulatory filings, approvals, reports, records, correspondence and other regulatory materials (including any related to reimbursement or pricing approvals), and all documents, data and other information related to Clinical Trials and other studies of Licensed Products (collectively, “Documentation and Approvals”); and 
 (ii)               permit Wistar and its licensees and sublicensees to utilize, reference, cross reference, incorporate in applications and filings, and otherwise have the benefit of all Documentation and Approvals.; and 
 31

 
 
  
 (iii)             provide to Wistar a copy of, and grant Wistar on mutually agreed terms a non-exclusive royalty-based, fully paid-up, perpetual, irrevocable, sublicensable license to, all patents and applications of Company and its Affiliates that improve or are otherwise related to the Licensed Patents or that cover a Licensed Product (“Company IP”).  Wistar shall be free to use Company IP in the course of developing Licensed Products and/or otherwise exploiting the Licensed Patents, including licensing such rights to third parties.
 9.7                       Provisions Surviving Termination or Expiration.  Company’s obligation to pay any amounts accrued but unpaid, and to discharge any obligations or responsibilities arising, prior to expiration or earlier termination of this Agreement shall survive such termination or expiration.  In addition, Sections 2.2.1, 3.10, 4.5.3, 7.1.6, 7.2, 9.2(viii), 9.3 9.4, 9.5, 9.6, 9.7, 9.8, 10.3, 10.4 and 10.9 and Articles 1, 6 and 8, the defined terms and provisions used or referenced therein, and any other provisions required to interpret the rights and obligations of the parties arising prior to the termination or expiration date shall survive expiration or termination of this Agreement.
 9.8                       Right to Payment Accrues During Term of Agreement.  Whenever a payment to Wistar with respect to sales of any Licensed Product is provided for in this Agreement, the right of Wistar to such payment shall accrue at the time such product is manufactured or produced during the Term of this Agreement.  Therefore any inventory or stocks of such products existing prior to the expiration or earlier termination of this Agreement but sold thereafter shall generate payment to Wistar in accordance with the applicable percentage or other method for determining the amount of such payment provided in this Agreement.  In such cases, Company shall promptly remit payment to Wistar after the receipt of consideration from sale of such products.
 Article 10 - ADDITIONAL PROVISIONS
 10.1                   Assignment.
 10.1.1.  This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective permitted assigns and successors in interest.  Except as expressly permitted in this Agreement, Company shall not assign, delegate or subcontract any of its rights or obligations under this Agreement without the prior written consent of Wistar. 
 10.1.2.  No such consent shall be required to assign this Agreement to a successor in connection with a merger or consolidation of Company, or to the purchaser of all or substantially all the assets of Company, provided that:  (i) Company is not in breach of this Agreement; (ii) such successor or purchaser shall agree in writing to be bound by the terms and conditions hereof prior to such assignment; (iii) Company shall provide Wistar with evidence to demonstrate that such successor or purchaser has or is likely to acquire, in a reasonable period of time, capital and personnel resources sufficient to fulfill the obligations it is assuming hereunder; (iv) Company shall notify Wistar in writing of any assignment and provide a copy of all assignment documents (pursuant to which such transferee shall have agreed in writing to be bound by the terms and conditions of this Agreement) to Wistar within thirty (30) days of assignment; and (v) ***. 
 32

 
 
  
 
10.1.3.  Failure of an assignee to agree to be bound by the terms hereof or failure of Company to notify Wistar and provide copies of assignment documentation shall be grounds for termination of this Agreement for default.  Any attempted assignment in contravention of this Section 10.1 shall be null and void. No assignment shall relieve Company of any obligation it has accrued prior to such assignment. 10.2                   No Waiver.  A waiver by either party of a breach or violation of any provision of this Agreement shall not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a waiver of any breach or violation of any other provision of this Agreement.
 10.3                   Independent Contractor.  Nothing herein shall be deemed to establish a relationship of principal and agent between Wistar and Company, nor any of their Sublicensees, Affiliates, agents or employees for any purpose whatsoever.  This Agreement shall not be construed as constituting Wistar and Company, or Wistar and any Sublicensees, as partners, or as creating any other form of legal association or arrangement which could impose liability upon one party for the act or failure to act of the other party.
 10.4                   Notices.  Any notice given under this Agreement shall be in writing and shall be deemed delivered when sent by prepaid, express, first class, certified or registered mail, or by overnight courier, with confirmed receipt, addressed to the parties as follows (or at such other addresses as the parties may notify each other in writing):
 If to Wistar:
 The Wistar Institute
 3601 Spruce Street
 Philadelphia, PA  19104
 Attn:  Office of Business Development
 With a copy to:  Attn:  Vice President, General Counsel, Secretary and Government Relations
 If to Company:
 Certainty Therapeutics, Inc.
 3150 Almaden Expressway, 
 Suite 250, San Jose, California 95118
 Attn:  Amit Kumar, Chief Executive Officer 
 33

 
 
  
 10.5                   Entire Agreement.  This Agreement, together with the Equity Documents, embodies the entire understanding between the parties relating to the subject matter hereof and supersedes the Option and all prior understandings and agreements, whether written or oral.  This Agreement may not be varied except by a written document signed by duly authorized representatives of both parties.
 10.6                   Severability.  Any of the provisions of this Agreement which are determined to be invalid or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining provisions hereof or affecting the validity or unenforceability of any of the terms of this Agreement in any other jurisdiction.
 10.7                   Headings; Interpretation.  Any article and section headings and captions used in this Agreement are for convenience of reference only and shall not affect its construction or interpretation. The words “include” or “including” shall be construed as incorporating, also, “but not limited to” or “without limitation.”  The parties acknowledge that each party has read and negotiated the language used in this Agreement.  Because all parties participated in negotiating and drafting this Agreement, no rule of construction shall apply to this Agreement which construes ambiguous language in favor of or against any party by reason of that party’s role in drafting this Agreement.
 10.8                   No Third Party Benefits.  Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties hereto or their permitted assigns, any benefits, rights or remedies.
 10.9                   Disputes; Governing Law; Jurisdiction; Arbitration.
 10.9.1.  In the case of any dispute, claim, question or disagreement arising out of or relating to this Agreement, or the parties’ activities hereunder, including any question regarding the existence, validity or termination of this Agreement, the parties shall use all reasonable efforts to settle such dispute, claim, question or disagreement by amicable agreement, including by escalation to the President and Chief Executive Officer of Wistar and Chief Executive Officer of Company, if necessary, prior to commencement of arbitration. 
 10.9.2.  This Agreement shall be construed, governed, interpreted and applied in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of law principles.  Any controversy or claim arising out of or relating to this contract, or the breach thereof, shall be settled by arbitration administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by  the arbitrator(s) may be entered in any court having jurisdiction thereof.
 34

 
 
  
 10.10               Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against the party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument.
 
  
 35
  
 
 
  
 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the Effective Date.
  
  	 THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
  
	  
	 CERTAINTY THERAPEUTICS, INC.

	 By:
	 /s/ Heather A. Steinman
	  
	 By:
	 /s/ Amit Kumar

	  
	 Heather A. Steinman, Ph.D., M.B.A.
	  
	 Name: Amit Kumar
 Title: Chief Executive Officer

	  
	 Vice President, Business Development and Executive Director, Technology Transfer
	  
	  
	  

	 Date:
	 November 9, 2017
	  
	 Date:
	 November 13, 2017

	 	 	 	 	 	

36

 
 
 
 LICENSE AGREEMENT
 BETWEEN
 THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
 AND
 CERTAINTY THERAPEUTICS, INC.
  
 INDEX OF SCHEDULES
  
 Schedule I – Licensed Patents 
 Schedule II – Quarterly Report

 37

 
 
   
 Schedule I 
 Licensed Patents
 	 Inventors
	 Serial No.
	 App. Type
	 File Date
	 Title

	 Alfredo Perales-Puchalt, Jose Conejo-Garcia
	 62/059,068
	 PPA1
	 10/02/2014
	 Methods and Compositions for Treating Cancer

	 Alfredo Perales-Puchalt, Jose Conejo-Garcia
	 62/202,824
	 PPA2
	 8/08/2015
	 Methods and Compositions for Treating Cancer

	 Alfredo Perales-Puchalt, Jose Conejo-Garcia
	 PCT/US2015/053128 
 Pub No.
 WO 2016/054153
	 PCT
	 9/30/2015
 Pub Date: 4/07/2016
	 Methods and Compositions for Treating Cancer

	 Alfredo Perales-Puchalt, Jose Conejo-Garcia
	 US15/515,442
 Pub No.
 US 2017/0226176 A1
	 US National Phase
	 9/30/2015 (5/29/2017)
 Pub Date: 8/10/2017
	 Methods and Compositions for Treating Cancer

	 Alfredo Perales-Puchalt, Jose Conejo-Garcia
	 15847792.7
 Pub No. EP2300815A
	 Europe National Phase
	 9/30/2015
 (4/29/2017)
 Pub Date: 8/09/2017
	 Methods and Compositions for Treating Cancer

	 Alfredo Perales-Puchalt, Jose Conejo-Garcia
	 201580065382.9
 Pub No. CN 106999552
	 China National Phase
	 9/30/2015
 (6/01/2017)
 Pub Date: 8/01/2017
	 Methods and Compositions for Treating Cancer

  
 
 
   
 Schedule II
 Quarterly Report 
 Per Section 3.8 of this Agreement, reports shall include at least the following, on a Licensed Product-by-Licensed Product and country-by-country basis: 
 A.                the numbers or quantity of each Licensed Product sold by Company, its Affiliates and each Sublicensee during the Calendar Quarter; 
 B.                 the gross amount billed and actually collected by Company, its Affiliates and Sublicensees for Licensed Products, and an accounting of any non-monetary consideration for each Licensed Product sold by Company, its Affiliates and each Sublicensee during the Calendar Quarter; 
 C.                deductions applicable to the sale of each Licensed Product during the Calendar Quarter, as provided in the definition of Net Sales;
 D.                average sale price during the Calendar Quarter;
 E.                 exchange rates used for currency conversion under Section 3.9.2 for the Calendar Quarter and the basis and methodology used;
 F.                 total royalties due to Wistar under Section 3.2.1 for the Calendar Quarter, as well as a detailed accounting of how such payments were calculated; 
 G.                milestone payments due to Wistar;
 H.                Minimum Annual Royalties and maintenance fees due to Wistar; 
 I.                   names and addresses of all Sublicensees of Company during the Calendar Quarter; 
 J.                  Non-Royalty Sublicensing Income received during the Calendar Quarter from each Sublicensee, identifying the types of payment as further described in the definition of Non-Royalty Sublicensing Income; 
 K.                description and product codes, or other Company identifier, of each Licensed Product sold during the Calendar Quarter; and
 L.                 a list of countries in which a First Commercial Sale occurred in the Calendar Quarter.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]